{
	"questions": [{
			"id": "63f03006f36125a426000018",
			"type": "summary",
			"body": "What were the results of the DESTINY-Breast04 Trial?",
			"chatgpt-out": {
				"queries": ["DESTINY-Breast04 trial results", "Trastuzumab deruxtecan efficacy in breast cancer", "Phase III study of trastuzumab deruxtecan in HER2-positive breast cancer", "Clinical trial of trastuzumab deruxtecan in breast cancer", "DESTINY-Breast04 trial design and outcomes", "HER2-targeted therapy in metastatic breast cancer", "Trastuzumab deruxtecan safety profile in breast cancer", "Antibody-drug conjugate therapy for breast cancer"],
				"short-ans": "The DESTINY-Breast04 trial was a phase III clinical trial that evaluated the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. The study found that trastuzumab deruxtecan significantly improved progression-free survival and overall response rate compared to standard treatment with trastuzumab emtansine. However, the treatment also had a higher incidence of interstitial lung disease as a side effect. Overall, the trial results suggest that trastuzumab deruxtecan may be an effective treatment option for patients with HER2-positive metastatic breast cancer.",
				"long-ans": "The DESTINY-Breast04 trial was a randomized, open-label, multicenter phase III study that evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer who had received prior treatment with trastuzumab emtansine (T-DM1). The trial enrolled 524 patients and randomized them in a 2:1 ratio to receive either T-DXd (n=347) or T-DM1 (n=177).The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. The trial found that T-DXd significantly improved PFS compared to T-DM1, with a median PFS of 16.4 months vs. 8.2 months (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.22-0.37; p<0.001). T-DXd also significantly improved ORR compared to T-DM1, with an ORR of 78.6% vs. 39.3% (p<0.001).However, the study also found that T-DXd had a higher incidence of interstitial lung disease (ILD) compared to T-DM1 (15.9% vs. 3.5%), with six deaths attributed to ILD in the T-DXd group. Other common adverse events associated with T-DXd included nausea, fatigue, and vomiting.In summary, the DESTINY-Breast04 trial demonstrated that T-DXd significantly improved PFS and ORR compared to",
				"exact_answer": ""
			}
		},
		{
			"id": "641ad941690f196b5100003d",
			"type": "yesno",
			"body": "Are LOQ and LOD the same?",
			"chatgpt-out": {
				"queries": ["LOQ vs. LOD", "Limit of quantification vs. limit of detection", "Analytical chemistry LOQ and LOD", "Clinical laboratory LOQ and LOD", "Biomedical assay sensitivity and specificity", "LOQ and LOD in medical research"],
				"short-ans": "LOQ (Limit of Quantification) and LOD (Limit of Detection) are two related but distinct concepts used in analytical chemistry and other fields to measure the sensitivity of a given method or assay. The LOQ represents the lowest concentration or amount of analyte that can be reliably measured with a specified degree of accuracy and precision. It is typically defined as the concentration at which the coefficient of variation (CV) of the measurements is less than a certain percentage (e.g., 10%). The LOD, on the other hand, represents the lowest concentration or amount of analyte that can be detected above the background noise or baseline signal. It is usually defined as the concentration that yields a signal-to-noise ratio (S/N) of a certain threshold (e.g., 3:1). In practice, the LOQ is usually higher than the LOD, as it requires a higher level of precision and accuracy.",
				"long-ans": "LOQ and LOD are two important parameters used to assess the sensitivity and accuracy of analytical methods and assays in various fields, including clinical chemistry, environmental monitoring, food safety, and drug development. The LOQ represents the lowest concentration or amount of analyte that can be quantified with a specified degree of accuracy and precision, while the LOD represents the lowest concentration or amount of analyte that can be detected above the background noise or baseline signal.In analytical chemistry, the LOQ is often defined as the concentration that yields a CV of less than 10%, while the LOD is defined as the concentration that yields a S/N ratio of 3:1. However, these thresholds can vary depending on the specific application and the level of precision required. In clinical chemistry, for example, the LOQ and LOD are often determined based on the analytical performance specifications of the assay, which may be influenced by factors such as the clinical decision limit and the biological variability of the analyte.It is important to note that the LOQ and LOD are not interchangeable terms and should not be used interchangeably. The LOQ is a measure of the lowest concentration or amount of analyte that can be reliably quantified, while the LOD is a measure of the lowest concentration or amount of analyte that can be detected. In practice, the LOQ is usually higher than the LOD, as it requires a higher level of precision and accuracy.In summary, understanding the difference between LOQ and LOD is critical for assessing the sensitivity and accuracy of analytical methods and assays in various fields. While both parameters represent important aspects of method performance, they are not the same and should be used appropriately depending on the specific application and requirements of the assay.",
				"exact_answer": "no"
			}
		},
		{
			"id": "642a029d57b1c7a315000011",
			"type": "summary",
			"body": "Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?",
			"chatgpt-out": {
				"queries": ["Function of histone acetylation", "Role of HATs in gene expression", "Epigenetic regulation by histone acetylation", "Histone acetylation and chromatin remodeling", "Lysine acetylation and protein function", "Acetylation of non-histone proteins"]

					,
				"short-ans": "Histone acetylation plays a crucial role in the regulation of gene expression and chromatin remodeling. By transferring acetyl groups from acetyl CoA to specific lysine residues on histones, histone acetyltransferases (HATs) neutralize the positive charge of histones and reduce their affinity for DNA, allowing for more open and accessible chromatin structures. This increased accessibility of chromatin facilitates the binding of transcription factors and other regulatory proteins, leading to the activation of gene expression. Conversely, the removal of acetyl groups by histone deacetylases (HDACs) leads to more compact chromatin structures and decreased gene expression. Additionally, histone acetylation has been implicated in other cellular processes, including DNA repair, cell cycle regulation, and cell differentiation.",
				"long-ans": "Histone acetylation is a fundamental epigenetic modification that regulates gene expression and chromatin structure in eukaryotic cells. This modification is catalyzed by histone acetyltransferases (HATs), which transfer acetyl groups from acetyl CoA to specific lysine residues on histones. The addition of acetyl groups neutralizes the positive charge of histones and reduces their affinity for DNA, leading to more open and accessible chromatin structures.The purpose of histone acetylation is to regulate gene expression by controlling the accessibility of DNA to transcription factors and other regulatory proteins. Specifically, acetylation of histones is associated with increased gene expression, while deacetylation of histones is associated with decreased gene expression. This is due to the fact that open chromatin structures allow for the binding of transcription factors and other regulatory proteins to promoter regions of genes, which facilitates transcription initiation and activation of gene expression. Conversely, more compact chromatin structures limit access to DNA and reduce gene expression.In addition to its role in gene expression regulation, histone acetylation has been implicated in other cellular processes, including DNA repair, cell cycle regulation, and cell differentiation. Acetylation of non-histone proteins, including transcription factors, nuclear receptors, and chaperones, has also been shown to affect protein function and cellular processes.In summary, histone acetylation is a crucial epigenetic modification that regulates gene expression and chromatin structure by neutralizing the positive charge of histones and reducing their affinity for DNA. This modification is catalyzed by histone acetyltransferases (HATs) and is associated with increased gene expression and other cellular processes.",
				"exact_answer": ""
			}
		},
		{
			"id": "6432fc0457b1c7a31500001f",
			"type": "factoid",
			"body": "Which gene is most frequently mutated in hereditary angioedema ?",
			"chatgpt-out": {
				"queries": ["Gene mutations in hereditary angioedema", "C1 inhibitor gene mutations in HAE", "SERPING1 mutations and HAE", "F12 gene mutations and HAE", "Angioedema and genetic mutations", "Hereditary angioedema genetics"],
				"short-ans": " Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent episodes of non-pitting edema affecting the skin, gastrointestinal tract, and upper respiratory tract. The condition is caused by mutations in the C1 inhibitor gene (SERPING1), which regulates the complement and kinin pathways. More than 300 different mutations have been identified in the SERPING1 gene, with the majority of mutations resulting in decreased or absent levels of functional C1 inhibitor protein. These mutations lead to uncontrolled activation of the complement and kinin pathways, resulting in the release of vasoactive peptides such as bradykinin, which causes increased vascular permeability and edema.In summary, hereditary angioedema is most frequently caused by mutations in the C1 inhibitor gene (SERPING1), which leads to uncontrolled activation of the complement and kinin pathways and release of vasoactive peptides such as bradykinin. Rare cases of HAE have been reported with mutations in the F12 gene, which is involved in the contact system pathway.",
				"long-ans": "Hereditary angioedema (HAE) is a rare inherited disorder that affects approximately 1 in 50,000 people worldwide. It is caused by mutations in the C1 inhibitor gene (SERPING1), which encodes a serine protease inhibitor that regulates the complement and kinin pathways. More than 300 different mutations have been identified in the SERPING1 gene, with the majority of mutations resulting in decreased or absent levels of functional C1 inhibitor protein. This leads to uncontrolled activation of the complement and kinin pathways, resulting in the release of vasoactive peptides such as bradykinin, which causes increased vascular permeability and edema.The severity and frequency of HAE attacks can vary widely among affected individuals, depending on the specific mutation and other genetic and environmental factors. There are three types of HAE, classified based on the underlying genetic defect and clinical features:Type I HAE: characterized by decreased levels of functional C1 inhibitor protein, usually due to mutations that impair protein production or stability.Type II HAE: characterized by normal or elevated levels of dysfunctional C1 inhibitor protein, usually due to mutations that impair protein function.Type III HAE: a rare form of HAE that affects primarily women and is associated with mutations in the F12 gene, which encodes coagulation factor XII. Type III HAE is often triggered by hormonal changes, such as pregnancy or oral contraceptive use, and may be associated with other medical conditions such as autoimmune disorders.Genetic testing is available for HAE and can help to confirm the diagnosis and guide treatment decisions. Treatment options for HAE include replacement therapy with C1 inhibitor protein, bradykinin receptor antagonists, and kallikrein inhibitors. Patients with HAE should also receive education and support to manage acute attacks and prevent triggers.In conclusion, mutations in the C1 inhibitor gene (SERPING1) are the most common cause of hereditary angioedema, leading to uncontrolled activation of the complement and kinin pathways and release of vasoactive peptides such as bradykinin. Rare cases of HAE have been reported with mutations in the F12 gene, which is involved in the contact system pathway. Understanding the genetics of HAE is essential for accurate diagnosis and appropriate management of the condition.",
				"exact_answer": ["C1 inhibitor gene (SERPING1)", "F12 gene", "Hereditary angioedema", "Contact system pathway", "Bradykinin"]
			}
		},
		{
			"id": "64178edb690f196b51000025",
			"type": "summary",
			"body": "What is casimersen\u0027s mechanism of action?",
			"chatgpt-out": {
				"queries": ["Casimersen MOA", "Antisense oligonucleotides and exon skipping", "Duchenne muscular dystrophy and casimersen", "Pharmacokinetics and pharmacodynamics of casimersen", "Clinical trials of casimersen", "RNA splicing modulation by casimersen"]

					,
				"short-ans": "Casimersen is a medication used in the treatment of Duchenne muscular dystrophy caused by a mutation in the DMD gene. It works by targeting a specific area in the messenger RNA (mRNA) sequence, leading to the skipping of exon 45 during pre-mRNA splicing. This results in a shortened but functional dystrophin protein, which is essential for muscle function.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the DMD gene that lead to the production of an abnormal dystrophin protein or the absence of dystrophin. Dystrophin is a crucial protein for muscle function, and its absence or abnormality results in progressive muscle weakness and wasting. Casimersen, also known as SRP-4045, is an antisense oligonucleotide medication that is designed to treat DMD caused by a specific mutation in the DMD gene that leads to exon 45 skipping.Casimersen's mechanism of action involves binding to a specific region in the mRNA sequence, which masks the exon 45 site during pre-mRNA splicing. This leads to the skipping of exon 45 during mRNA processing, resulting in a shortened but functional dystrophin protein. The shortened protein is still able to provide support and structure to muscle cells, which can help improve muscle function in DMD patients. Casimersen is administered through intravenous infusion, and it has been shown to be generally safe and well-tolerated, with no serious adverse events reported in clinical trials.Several studies have demonstrated the efficacy of casimersen in improving muscle function in DMD patients with exon 45 skipping mutations. In a phase 3 clinical trial, patients who received casimersen showed significant improvement in walking distance compared to those who received a placebo. Casimersen is part of a group of exon-skipping therapies that target specific mutations in the DMD gene and has shown promising results in clinical trials. However, further studies are needed to evaluate its long-term efficacy and safety.",
				"exact_answer": ""
			}
		},
		{
			"id": "6402bf2b201352f04a000007",
			"type": "summary",
			"body": "What is the mechanism of action of tiragolumab?",
			"chatgpt-out": {
				"queries": ["tiragolumab AND mechanism of action",
					"tiragolumab AND PD-1",
					"tiragolumab AND immunotherapy",
					"tiragolumab AND cancer",
					"tiragolumab AND clinical trials"
				],
				"short-ans": "Tiragolumab is a drug that is used as an immunotherapy to treat various types of cancer, such as lung cancer and breast cancer. Specifically, tiragolumab is a monoclonal antibody that targets and blocks the PD-1 protein. PD-1 is a receptor found on the surface of immune cells, including T cells. When PD-1 binds to another protein called PD-L1, it sends a signal to the immune cell to stop attacking the target cell. This mechanism is hijacked by cancer cells to evade the immune system and avoid being attacked by T cells. Tiragolumab blocks the PD-1 protein from binding to PD-L1, allowing T cells to recognize and attack cancer cells.",
				"long-ans": "Tiragolumab is a monoclonal antibody that is used as an immunotherapy to treat various types of cancer, such as lung cancer and breast cancer. Tiragolumab works by blocking the PD-1 protein, which is a receptor found on the surface of immune cells, including T cells. When PD-1 binds to another protein called PD-L1, it sends a signal to the immune cell to stop attacking the target cell. This mechanism is hijacked by cancer cells to evade the immune system and avoid being attacked by T cells. By blocking the PD-1 protein, tiragolumab prevents the cancer cells from inhibiting the immune response, allowing T cells to recognize and attack cancer cells.Tiragolumab is typically administered via intravenous infusion, and it is often used in combination with other cancer treatments, such as chemotherapy and other immunotherapies. Clinical trials of tiragolumab have shown promising results in improving overall survival and progression-free survival in people with various types of cancer. However, like all drugs, tiragolumab can have side effects, including fatigue, diarrhea, and immune-related adverse events such as pneumonitis and colitis. As with any medical treatment, it is important to discuss the potential benefits and risks of tiragolumab with a healthcare provider.",
				"exact_answer": ""
			}
		},
		{
			"id": "641d8fd6690f196b51000041",
			"type": "list",
			"body": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?",
			"chatgpt-out": {
				"queries": ["NMOSD serum biomarkers disease activity", "aquaporin-4 antibody NMOSD biomarkers", "glial fibrillary acidic protein NMOSD biomarkers", "myelin oligodendrocyte glycoprotein NMOSD biomarkers", "C-reactive protein NMOSD biomarkers"]

					,
				"short-ans": "Neuromyelitis Optica Spectrum Disorders (NMOSD) is an autoimmune disorder that affects the central nervous system, leading to unpredictable relapses and remissions that can result in severe disability or even death. Serum biomarkers have been proposed to monitor disease activity in NMOSD.One of the most well-established biomarkers is the aquaporin-4 antibody (AQP4-ab), which is present in the majority of NMOSD patients and is associated with a higher risk of relapse. AQP4-ab binds to aquaporin-4, a protein found in astrocytes, leading to astrocytic damage and inflammation. The levels of AQP4-ab in the serum have been shown to correlate with disease activity and severity in NMOSD.Other potential serum biomarkers include glial fibrillary acidic protein (GFAP), myelin oligodendrocyte glycoprotein (MOG), and C-reactive protein (CRP). GFAP is a biomarker of astrocytic damage and has been shown to correlate with NMOSD disease activity. MOG is a protein found in myelin, and its antibodies have been detected in some NMOSD patients. CRP is a general marker of inflammation and has been associated with NMOSD disease activity in some studies.",
				"long-ans": "Neuromyelitis Optica Spectrum Disorders (NMOSD) are autoimmune disorders that affect the central nervous system, resulting in unpredictable relapses and remissions that can lead to severe disability or even death. Serum biomarkers have been proposed to monitor disease activity in NMOSD.The most widely studied biomarker is the aquaporin-4 antibody (AQP4-ab), which is present in the majority of NMOSD patients and is associated with a higher risk of relapse. AQP4-ab binds to aquaporin-4, a protein found in astrocytes, leading to astrocytic damage and inflammation. The levels of AQP4-ab in the serum have been shown to correlate with disease activity and severity in NMOSD.In addition to AQP4-ab, other potential serum biomarkers for monitoring NMOSD disease activity include glial fibrillary acidic protein (GFAP), myelin oligodendrocyte glycoprotein (MOG), and C-reactive protein (CRP). GFAP is a biomarker of astrocytic damage and has been shown to correlate with NMOSD disease activity. MOG is a protein found in myelin, and its antibodies have been detected in some NMOSD patients. CRP is a general marker of inflammation and has been associated with NMOSD disease activity in some studies.Although these biomarkers show promise in monitoring NMOSD disease activity, they are not yet routinely used in clinical practice. Further research is needed to validate their usefulness and establish standardized protocols for their use in monitoring NMOSD disease activity.",
				"exact_answer": "[Serum biomarkers, Neuromyelitis Optica Spectrum Disorders (NMOSD), aquaporin-4 antibody (AQP4-ab), glial fibrillary acidic protein (GFAP), myelin oligodendrocyte glycoprotein (MOG), and C-reactive protein (CRP)]"
			}
		},
		{
			"id": "6429d5c557b1c7a315000006",
			"type": "list",
			"body": "What are the major thrombotic complications in patients with COVID-19?",
			"chatgpt-out": {
				"queries": ["COVID-19 thrombosis complications", "COVID-19 venous thromboembolism", "COVID-19 arterial thrombosis", "COVID-19 coagulopathy", "COVID-19 hypercoagulability"]

					,
				"short-ans": "COVID-19 is a viral illness caused by the SARS-CoV-2 virus. While COVID-19 primarily affects the respiratory system, it is now recognized that COVID-19 can also cause thrombotic complications. Thrombosis refers to the formation of a blood clot within a blood vessel, which can lead to serious complications such as stroke, heart attack, and pulmonary embolism.The major thrombotic complications seen in patients with COVID-19 include venous thromboembolism (VTE), arterial thrombosis, and disseminated intravascular coagulation (DIC). VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE), which can be life-threatening if not promptly diagnosed and treated. Arterial thrombosis can lead to stroke or myocardial infarction (heart attack). DIC is a condition where the body's clotting system becomes overactive and can lead to multiple clots throughout the body.The exact mechanisms underlying COVID-19-related thrombotic complications are not yet fully understood. However, it is believed that the virus can directly damage the blood vessels, activate the clotting system, and cause inflammation, all of which can contribute to the formation of blood clots.",
				"long-ans": "COVID-19 is a viral illness caused by the SARS-CoV-2 virus that primarily affects the respiratory system, but it is now recognized that COVID-19 can also cause thrombotic complications. Thrombosis is the formation of a blood clot within a blood vessel, which can lead to serious complications such as stroke, heart attack, and pulmonary embolism.The major thrombotic complications seen in patients with COVID-19 include venous thromboembolism (VTE), arterial thrombosis, and disseminated intravascular coagulation (DIC). VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE), which can be life-threatening if not promptly diagnosed and treated. Arterial thrombosis can lead to stroke or myocardial infarction (heart attack). DIC is a condition where the body's clotting system becomes overactive and can lead to multiple clots throughout the body.Studies have shown that COVID-19 patients are at a higher risk of thrombotic complications than patients with other respiratory illnesses. The exact mechanisms underlying COVID-19-related thrombotic complications are not yet fully understood, but it is believed that the virus can directly damage the blood vessels, activate the clotting system, and cause inflammation, all of which can contribute to the formation of blood clots.Several risk factors for COVID-19-related thrombotic complications have been identified, including advanced age, obesity, hypertension, diabetes, and cardiovascular disease. Prophylactic anticoagulation therapy is often used in hospitalized COVID-19 patients to prevent thrombotic complications, but the optimal dosing and duration of anticoagulation therapy are still under investigation.In addition to anticoagulation therapy, other treatments for COVID",
				"exact_answer": ["COVID-19", "thrombotic complications", "venous thromboembolism (VTE)", "deep vein thrombosis (DVT)", "pulmonary embolism (PE)", "arterial thrombosis", "disseminated intravascular coagulation (DIC)", "SARS-CoV-2", "risk factors", "anticoagulation therapy", "stroke", "myocardial infarction", "inflammation"]
			}
		},
		{
			"id": "6433012b57b1c7a315000022",
			"type": "summary",
			"body": "What is Cinryze?",
			"chatgpt-out": {
				"queries": ["Cinryze indication", "Cinryze mechanism of action", "Cinryze clinical trials", "Cinryze safety", "Cinryze efficacy"]

					,
				"short-ans": "Cinryze is a medication used for the treatment of hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling in different parts of the body, including the face, extremities, and airway. HAE attacks can be life-threatening if they involve the airway. Cinryze contains C1 esterase inhibitor, a protein that is deficient in patients with HAE.",
				"long-ans": " Cinryze is a medication used for the treatment of hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling in different parts of the body, including the face, extremities, and airway. HAE attacks can be life-threatening if they involve the airway. Cinryze contains C1 esterase inhibitor, a protein that is deficient in patients with HAE.C1 esterase inhibitor works by inhibiting the activity of the complement system, a part of the immune system that plays a role in inflammation. By inhibiting the complement system, C1 esterase inhibitor reduces the likelihood of HAE attacks. Cinryze is given by intravenous infusion and has been shown to be effective in reducing the frequency and severity of HAE attacks in clinical trials.Cinryze was approved by the US Food and Drug Administration (FDA) in 2008 for routine prophylaxis against HAE attacks in adolescents and adults. It is also approved for use in Europe and other countries. Cinryze has been evaluated in several clinical trials, including a randomized, double-blind, placebo-controlled trial that showed a significant reduction in the frequency and severity of HAE attacks with Cinryze prophylaxis.Cinryze is generally well-tolerated, with few side effects reported. The most common side effect is headache, but other side effects such as nausea, vomiting, and fever may occur. Cinryze is considered safe for use during pregnancy and lactation.In addition to Cinryze, other medications are available for the treatment of HAE, including other C1 esterase inhibitors and bradykinin B2 receptor antagonists. The choice of medication depends on several factors, including the patient's age, medical history, and the severity of HAE attacks.",
				"exact_answer": "no"
			}
		},
		{
			"id": "64179337690f196b51000034",
			"type": "yesno",
			"body": "Do machine learning-based methods outperform statistical methods for survival analysis?",
			"chatgpt-out": {
				"queries": ["Machine learning survival analysis", "Statistical survival analysis", "Machine learning vs statistical methods for survival analysis", "Comparison of machine learning and statistical methods for survival analysis"]

					,
				"short-ans": "Survival analysis is a statistical method used to analyze data on the time until an event of interest occurs, such as death or disease recurrence. While traditional statistical methods have been widely used for survival analysis, machine learning-based methods have gained increasing attention in recent years due to their ability to handle high-dimensional data and complex relationships among variables.Several studies have compared the performance of machine learning-based methods and traditional statistical methods for survival analysis. While the results have been mixed, some studies have suggested that machine learning-based methods may outperform traditional statistical methods in certain scenarios. For example, machine learning-based methods may be better suited for handling high-dimensional data with complex interactions, while traditional statistical methods may be more appropriate for smaller datasets with simpler relationships.However, it is important to note that the choice of method depends on several factors, including the specific research question, the type and amount of data available, and the researcher's level of expertise in the different methods.",
				"long-ans": "Survival analysis is a statistical method used to analyze data on the time until an event of interest occurs, such as death or disease recurrence. While traditional statistical methods have been widely used for survival analysis, machine learning-based methods have gained increasing attention in recent years due to their ability to handle high-dimensional data and complex relationships among variables.Several studies have compared the performance of machine learning-based methods and traditional statistical methods for survival analysis. While the results have been mixed, some studies have suggested that machine learning-based methods may outperform traditional statistical methods in certain scenarios. For example, a study published in the Journal of Clinical Oncology found that machine learning-based methods had higher predictive accuracy than traditional Cox proportional hazards models for predicting survival outcomes in breast cancer patients.Another study published in the Journal of Medical Internet Research demonstrated that machine learning-based methods were more accurate in predicting in-hospital mortality than traditional logistic regression models in patients with sepsis. Similarly, a study published in the Journal of Clinical Epidemiology showed that machine learning-based methods were more accurate than traditional Cox proportional hazards models for predicting cardiovascular disease risk in a large cohort of patients.However, it is important to note that the choice of method depends on several factors, including the specific research question, the type and amount of data available, and the researcher's level of expertise in the different methods. Machine learning-based methods can be more complex to implement and may require larger sample sizes and more advanced statistical skills, whereas traditional statistical methods are often simpler and more widely understood. Ultimately, the choice of method should be based on a careful consideration of these factors and the specific needs of the research question.",
				"exact_answer": "no"
			}
		},
		{
			"id": "63f03c47f36125a42600001e",
			"type": "factoid",
			"body": "ZF2001 is used for which disease?",
			"chatgpt-out": {
				"queries": [
					["ZF2001 indication", "ZF2001 clinical trials", "ZF2001 safety", "ZF2001 efficacy", "ZF2001 disease"]

				],
				"short-ans": " ZF2001 is a COVID-19 vaccine developed by Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., a Chinese biopharmaceutical company. The vaccine is based on a recombinant protein subunit approach, which involves using a harmless piece of the SARS-CoV-2 virus to stimulate an immune response. The vaccine is administered in two doses given three weeks apart.As of April 2021, ZF2001 has been granted conditional marketing authorization in China for use in individuals aged 18 and older. The safety and efficacy of ZF2001 have been evaluated in several clinical trials, including a phase 3 trial that enrolled over 29,000 participants in China. The trial found that ZF2001 was 79.3% effective in preventing symptomatic COVID-19, and 100% effective in preventing severe disease.",
				"long-ans": "ZF2001 is a COVID-19 vaccine developed by Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., a Chinese biopharmaceutical company. The vaccine is based on a recombinant protein subunit approach, which involves using a harmless piece of the SARS-CoV-2 virus to stimulate an immune response. The vaccine contains the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2, which is the part of the virus that binds to human cells.As of April 2021, ZF2001 has been granted conditional marketing authorization in China for use in individuals aged 18 and older. The safety and efficacy of ZF2001 have been evaluated in several clinical trials, including a phase 3 trial that enrolled over 29,000 participants in China. The trial found that ZF2001 was 79.3% effective in preventing symptomatic COVID-19, and 100% effective in preventing severe disease.Another phase 3 trial of ZF2001 is ongoing in Ecuador, Peru, and Indonesia, with a target enrollment of approximately 33,000 participants. The trial is evaluating the safety and efficacy of the vaccine in preventing COVID-19 in individuals aged 18 and older. In addition, a phase 1/2 trial of ZF2001 in children and adolescents aged 3 to 17 is currently underway in China.ZF2001 is one of several COVID-19 vaccines that have been developed and authorized for emergency use around the world. Other authorized vaccines include those developed by Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, and Sinovac, among others. The choice of vaccine depends on several factors, including the local availability of vaccines, the specific needs of the population, and the vaccine's safety and efficacy profile.",
				"exact_answer": ["COVID-19 vaccine ZF2001", "Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.", "Receptor-binding domain (RBD)", "Spike protein", "Phase 3 clinical trial"]
			}
		},
		{
			"id": "642c82c557b1c7a315000012",
			"type": "factoid",
			"body": "What mammal has the lowest known chromosome number?",
			"chatgpt-out": {
				"queries": ["Mammal with lowest chromosome number", "Karyotype of mammals", "Chromosome number in mammals", "Animal genome sequencing"]

					,
				"short-ans": " The mammal with the lowest known chromosome number is the Japanese field mouse (Apodemus argenteus), which has a diploid chromosome number of just 24. This is in contrast to the human diploid chromosome number of 46.",
				"long-ans": "Karyotype analysis, which involves examining the number, size, and shape of chromosomes in a cell, has been an important tool for studying the evolutionary relationships among species. While the diploid chromosome number varies widely among mammals, ranging from as few as 6 in some species of shrews to as many as 116 in the red viscacha rat, the Japanese field mouse (Apodemus argenteus) has the lowest known chromosome number among all mammals, with a diploid number of just 24.The low chromosome number in the Japanese field mouse is thought to be due to extensive chromosomal fusions that have occurred during its evolution. While the precise evolutionary history of the Japanese field mouse is still being studied, the species is believed to have diverged from its closest relative, the Eurasian field mouse (Apodemus agrarius), approximately 2 million years ago.The sequencing of animal genomes has provided new insights into the evolution of chromosome number and structure. For example, a study published in Nature Genetics in 2008 compared the genomes of humans, mice, and rats and found that many of the structural changes that differentiate these species are due to variations in the number and position of repeated DNA sequences. Understanding the mechanisms that underlie these structural changes in chromosomes may provide new insights into the evolution of different mammalian lineages.",
				"exact_answer": ["Japanese field mouse", "Apodemus argenteus", "Diploid chromosome number", "Karyotype analysis", "Chromosomal fusions"]




			}
		},
		{
			"id": "6429b41757b1c7a315000004",
			"type": "list",
			"body": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
			"chatgpt-out": {
				"queries": ["Histone modifications amino acids", "Histone acetyltransferases targets", "Histone methyltransferases targets", "Epigenetic modifications", "Histone code"]

					,
				"short-ans": " Histones are proteins that play a critical role in regulating gene expression by packaging and organizing DNA within the nucleus. Histones can be modified by the addition of chemical groups such as acetyl and methyl groups, which are added to specific amino acids within the histone protein. These modifications are known as epigenetic modifications, and they can either activate or repress gene expression.Histone acetyltransferases (HATs) add acetyl groups to the lysine amino acid residues within histones, while histone methyltransferases (HMTs) add methyl groups to either lysine or arginine residues. HATs are responsible for adding activating marks to histones, while HMTs can add either activating or repressing marks depending on the specific amino acid targeted and the number of methyl groups added.Lysine 9 and 14 on histone H3 are commonly targeted by HATs and are associated with transcriptional activation. In contrast, lysine 27 and 9 on histone H3 are targeted by HMTs and are associated with transcriptional repression. However, the specific amino acids targeted by HATs and HMTs can vary depending on the specific histone protein and the context of the chromatin environment.",
				"long-ans": "Epigenetic modifications such as histone acetylation and methylation play a critical role in regulating gene expression by modulating the chromatin structure and accessibility of DNA to transcription factors and RNA polymerase. The addition of acetyl and methyl groups to specific amino acids within histones is a dynamic and tightly regulated process that is mediated by a complex network of enzymes and regulatory factors.Histone acetyltransferases (HATs) and histone methyltransferases (HMTs) are responsible for adding acetyl and methyl groups, respectively, to specific lysine and arginine residues within histone proteins. These enzymes play a critical role in establishing the histone code, which refers to the specific combination of histone modifications that is associated with a particular gene expression state.HATs add acetyl groups to the epsilon-amino group of lysine residues within the N-terminal tails of histones. This modification is associated with transcriptional activation and is thought to neutralize the positive charge on the lysine residue, thereby weakening the interaction between the positively charged histones and the negatively charged DNA. The specific amino acids targeted by HATs can vary depending on the specific histone protein and the context of the chromatin environment, but lysine 9 and 14 on histone H3 are commonly targeted by HATs.In contrast, HMTs add methyl groups to either lysine or arginine residues within the histone protein. This modification can either activate or repress gene expression depending on the specific amino acid targeted and the number of methyl groups added. For example, lysine 4 on histone H3 is associated with transcriptional activation when it is mono- or di-methylated, while it is associated with repression when it is tri-methylated. Similarly, lysine 9 and 27 on histone H3 are associated with transcriptional repression when they are",
				"exact_answer": ["Histones", "Acetyl groups", "Methyl groups", "Lysine", "Arginine"]




			}
		},
		{
			"id": "643305b257b1c7a315000025",
			"type": "factoid",
			"body": "Which company produces Ruconest?",
			"chatgpt-out": {
				"queries": ["Ruconest manufacturer", "Rhucin manufacturer", "C1 esterase inhibitor manufacturer", "Plasma-derived therapies", "Hereditary angioedema treatment"]

					,
				"short-ans": "Ruconest, also known as Rhucin or conestat alfa, is a plasma-derived therapy used for the treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients. It works by replacing the deficient C1 esterase inhibitor protein in patients with HAE, which helps to control swelling and inflammation. Ruconest is manufactured by Pharming Group NV, a Dutch biopharmaceutical company that specializes in the development and production of innovative protein therapeutics.",
				"long-ans": "Ruconest is a C1 esterase inhibitor (C1-INH) protein replacement therapy that is used for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare genetic disorder that is characterized by recurrent episodes of swelling in various parts of the body, including the face, limbs, and abdomen. It is caused by a deficiency or dysfunction of C1-INH, a protein that regulates the production of bradykinin, a peptide that increases vascular permeability and causes inflammation.Ruconest is a plasma-derived therapy that is produced by Pharming Group NV, a Dutch biopharmaceutical company that specializes in the development and production of innovative protein therapeutics. Ruconest was first approved by the European Medicines Agency (EMA) in 2010 for the treatment of acute attacks of HAE in adult and adolescent patients. It was subsequently approved by the U.S. Food and Drug Administration (FDA) in 2014.Plasma-derived therapies like Ruconest are produced from human blood plasma, which is collected from healthy donors and processed to extract the desired therapeutic proteins. These therapies are subject to rigorous safety and quality control measures to minimize the risk of transmission of infectious agents, such as viruses and prions, that may be present in the plasma.",
				"exact_answer": ["Pharming Group NV", "Ruconest", "C1 esterase inhibitor", "Hereditary angioedema", "Plasma-derived therapies"]




			}
		},
		{
			"id": "641635fa690f196b5100001c",
			"type": "factoid",
			"body": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
			"chatgpt-out": {
				"queries": ["Duchenne muscular dystrophy diagnosis age", "Clinical presentation Duchenne muscular dystrophy", "Motor milestones Duchenne muscular dystrophy", "Creatine kinase levels Duchenne muscular dystrophy", "Genetic testing Duchenne muscular dystrophy"]

					,
				"short-ans": "Duchenne muscular dystrophy (DMD) is a genetic disorder that affects muscle function and leads to progressive muscle weakness and wasting. It is caused by a mutation in the DMD gene, which codes for the protein dystrophin. The age of diagnosis for DMD can vary, but it is typically around 3-5 years of age.Children with DMD may have delayed motor milestones, such as walking and running, and may experience difficulty climbing stairs and getting up from a seated position. They may also exhibit a waddling gait and have enlarged calf muscles. Elevated creatine kinase (CK) levels in the blood can also be a clue for diagnosis, as CK is released into the bloodstream when muscle fibers are damaged.Genetic testing can confirm the diagnosis of DMD, and it is recommended for individuals with clinical features suggestive of the condition, such as delayed motor milestones or elevated CK levels. Early diagnosis is important for initiating appropriate medical and supportive interventions to improve outcomes and quality of life for individuals with DMD.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a genetic disorder that affects approximately 1 in 5000 male births and is characterized by progressive muscle weakness and wasting. The age of diagnosis for DMD can vary, but it is typically around 3-5 years of age.Clinical features of DMD include delayed motor milestones, such as walking and running, and difficulty climbing stairs and getting up from a seated position. Children with DMD may also exhibit a waddling gait and have enlarged calf muscles. Muscle weakness and wasting typically begin in the lower extremities and progress to involve the upper extremities and trunk.Elevated creatine kinase (CK) levels in the blood can also be a clue for diagnosis, as CK is released into the bloodstream when muscle fibers are damaged. However, CK levels can also be elevated in other conditions, so genetic testing is necessary to confirm the diagnosis of DMD.Genetic testing for DMD can be performed using a variety of methods, including multiplex ligation-dependent probe amplification (MLPA), next-generation sequencing (NGS), and Sanger sequencing. These tests can detect mutations in the DMD gene, which codes for the protein dystrophin. Dystrophin is an important component of muscle fibers and is essential for maintaining muscle structure and function.Early diagnosis of DMD is important for initiating appropriate medical and supportive interventions to improve outcomes and quality of life for individuals with the condition. These interventions may include physical therapy, orthopedic management, respiratory support, and medications that can help slow the progression of muscle weakness and wasting.",
				"exact_answer": ["Duchenne muscular dystrophy", "Age of diagnosis", "Genetic testing", "Creatine kinase levels", "Delayed motor milestones"]




			}
		},
		{
			"id": "6402c868201352f04a00000b",
			"type": "yesno",
			"body": "Was erythropoietin effective for optic neuritis in the TONE trial?",
			"chatgpt-out": {
				"queries": ["TONE trial erythropoietin optic neuritis", "Erythropoietin optic neuritis clinical trial", "Optic neuritis treatment TONE trial", "Visual function outcomes erythropoietin optic neuritis", "Randomized controlled trial erythropoietin optic neuritis"],
				"short-ans": "The TONE (Treatment of Optic Neuritis with Erythropoietin) trial was a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of erythropoietin (EPO) in the treatment of acute optic neuritis. The study included 92 participants with acute optic neuritis who were randomly assigned to receive either EPO or placebo for a period of 4 weeks.The results of the TONE trial showed that there was no significant difference in the primary outcome measure, which was change in visual function at 90 days, between the EPO and placebo groups. In addition, there were no significant differences in the secondary outcome measures, which included change in visual function at other time points and rate of conversion to multiple sclerosis.Based on these findings, the TONE trial did not demonstrate a significant benefit of EPO in the treatment of acute optic neuritis.",
				"long-ans": "Optic neuritis is an inflammatory condition that affects the optic nerve and can cause vision loss or impairment. Erythropoietin (EPO) is a hormone that stimulates the production of red blood cells and has been shown to have neuroprotective effects in animal models of optic neuritis.The TO NE (Treatment of Optic Neuritis with Erythropoietin) trial was a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of EPO in the treatment of acute optic neuritis. The study included 92 participants with acute optic neuritis who were randomly assigned to receive either EPO or placebo for a period of 4 weeks.The primary outcome measure of the TONE trial was change in visual function at 90 days, as measured by the Low Contrast Sloan Letter charts. The results showed that there was no significant difference in the change in visual function between the EPO and placebo groups at 90 days. In addition, there were no significant differences in the secondary outcome measures, which included change in visual function at other time points and rate of conversion to multiple sclerosis.Based on these findings, the TONE trial did not demonstrate a significant benefit of EPO in the treatment of acute optic neuritis. However, it is important to note that the trial had a relatively small sample size and further studies are needed to confirm these results. Other potential neuroprotective treatments for optic neuritis are currently under investigation, including anti-inflammatory agents and neurotrophic factors.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6424154d690f196b5100004a",
			"type": "summary",
			"body": "What is the R value with respect to hepatoxicity",
			"chatgpt-out": {
				"queries": ["hepatotoxicity R value", "R value liver toxicity", "correlation R value hepatotoxicity", "hepatotoxicity Pearson correlation coefficient", "R squared value liver toxicity"],
				"short-ans": "The R value, also known as the correlation coefficient, is a statistical measure used to determine the strength and direction of the relationship between two variables. In the context of hepatotoxicity, the R value can be used to assess the correlation between exposure to a substance and its potential liver toxicity. A higher R value indicates a stronger correlation, while a lower R value suggests a weaker relationship.",
				"long-ans": "Hepatotoxicity refers to liver damage caused by exposure to certain substances, including drugs, chemicals, and herbal remedies. The R value, or correlation coefficient, is a statistical measure that can be used to assess the strength and direction of the relationship between two variables. In the context of hepatotoxicity, the R value can be used to determine the correlation between exposure to a substance and its potential liver toxicity. For example, a study may use the R value to assess the correlation between a particular drug and the likelihood of developing liver damage. A higher R value indicates a stronger correlation between the two variables, while a lower R value suggests a weaker relationship. Additionally, the R value can be used to calculate the coefficient of determination, or R-squared value, which provides information on the proportion of variation in the dependent variable (in this case, liver toxicity) that can be explained by the independent variable (the substance exposure). Several studies have used the R value to assess the relationship between various substances and hepatotoxicity, including herbal remedies, dietary supplements, and prescription medications. Overall, the R value can be a useful tool in evaluating the potential liver toxicity of a substance and identifying possible risk factors.",
				"exact_answer": ""
			}
		},
		{
			"id": "64299b6a57b1c7a315000001",
			"type": "yesno",
			"body": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
			"chatgpt-out": {
				"queries": ["COVID-19 Omicron severity", "Omicron variant clinical outcomes", "COVID-19 variant comparison severity", "Omicron vs other variants disease severity", "SARS-CoV-2 Omicron severity"],
				"short-ans": "Preliminary data suggests that infection caused by the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, may be less severe than infection caused by other variants. Studies have shown that people infected with the Omicron variant may experience milder symptoms, be less likely to require hospitalization, and have a lower risk of death compared to those infected with earlier variants such as Delta. However, it is important to note that the severity of illness can vary greatly depending on individual factors such as age, underlying health conditions, and vaccination status.",
				"long-ans": "The Omicron variant of SARS-CoV-2, first identified in South Africa in November 2021, has quickly spread across the globe and become the dominant strain of the virus in many countries. While much is still unknown about the Omicron variant, early data suggests that it may be less severe than infection caused by other variants such as Delta. Several studies have reported milder symptoms and lower rates of hospitalization and death among people infected with Omicron compared to earlier variants. For example, a study conducted in South Africa found that the risk of hospitalization and death was significantly lower among patients infected with Omicron compared to those infected with Delta. Another study conducted in the United Kingdom found that people infected with Omicron were less likely to require hospitalization compared to those infected with Delta.Despite these promising findings, it is important to note that the severity of illness can vary greatly depending on individual factors such as age, underlying health conditions, and vaccination status. In addition, the Omicron variant is highly transmissible and can still cause serious illness and death, particularly among unvaccinated individuals. Ongoing research is needed to fully understand the clinical outcomes associated with the Omicron variant and to inform public health strategies for controlling the spread of the virus.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6432ffdf57b1c7a315000021",
			"type": "summary",
			"body": "What is hereditary angioedema?",
			"chatgpt-out": {
				"queries": ["hereditary angioedema overview", "genetic basis of angioedema", "clinical presentation of hereditary angioedema", "treatment of hereditary angioedema", "pathophysiology of angioedema"],
				"short-ans": "Hereditary angioedema (HAE) is a rare genetic disorder that results in episodes of swelling in various parts of the body, including the skin, gastrointestinal tract, and upper airway. These episodes can be triggered by a range of factors, including stress, injury, and certain medications. HAE is caused by mutations in the genes that control the production of proteins involved in regulating the immune system and inflammation. Symptoms of HAE can be severe and life-threatening, particularly when swelling occurs in the upper airway. There is currently no cure for HAE, but treatments such as medications and lifestyle modifications can help manage symptoms and reduce the frequency and severity of attacks.",
				"long-ans": "Hereditary angioedema (HAE) is a rare genetic disorder that affects an estimated 1 in 50,000 individuals worldwide. The disorder is characterized by recurrent episodes of swelling in various parts of the body, including the skin, gastrointestinal tract, and upper airway. The swelling can be spontaneous or triggered by a range of factors, including stress, injury, and certain medications. Symptoms of HAE can be severe and life-threatening, particularly when swelling occurs in the upper airway, which can lead to difficulty breathing and even death.HAE is caused by mutations in the genes that control the production of proteins involved in regulating the immune system and inflammation. Specifically, the disorder is associated with a deficiency or dysfunction of C1 esterase inhibitor, a protein that helps regulate the complement system, which is part of the immune system. The exact mechanism by which C1 esterase inhibitor deficiency or dysfunction leads to the symptoms of HAE is not fully understood, but it is thought to involve increased activation of the complement system and other inflammatory pathways.Diagnosis of HAE typically involves a combination of clinical evaluation, laboratory testing, and genetic analysis. Treatment options for HAE include medications such as plasma-derived or recombinant C1 esterase inhibitors, bradykinin receptor antagonists, and antifibrinolytic agents. Lifestyle modifications such as avoiding triggers and practicing stress reduction techniques may also be helpful in managing symptoms and reducing the frequency and severity of attacks. Despite these treatments, HAE remains a chronic and potentially life-threatening disorder, highlighting the need for ongoing research and treatment development.",
				"exact_answer": ""
			}
		},
		{
			"id": "64178ec2690f196b51000024",
			"type": "summary",
			"body": "What is viltolarsen\u0027s mechanism of action?",
			"chatgpt-out": {
				"queries": ["viltolarsen mechanism of action", "how does viltolarsen work", "viltolarsen pharmacodynamics", "mode of action of viltolarsen", "viltolarsen molecular mechanism"],
				"short-ans": "Viltolarsen is a medication used in the treatment of Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness and wasting. Viltolarsen works by targeting a specific genetic mutation in the dystrophin gene, which is responsible for producing a protein called dystrophin that is essential for maintaining muscle function. The medication is designed to help skip over the faulty section of the dystrophin gene, allowing the production of a shortened but still functional form of dystrophin.",
				"long-ans": " Duchenne muscular dystrophy (DMD) is a rare genetic disorder caused by mutations in the dystrophin gene, which is responsible for producing a protein called dystrophin that is essential for maintaining muscle function. Viltolarsen is a medication that has been approved for the treatment of DMD in patients who have a confirmed genetic mutation amenable to exon 53 skipping.Viltolarsen works by binding to a specific segment of the messenger RNA (mRNA) molecule, called the exon 53 splice site, which is located near the mutated region of the dystrophin gene. This binding promotes the skipping of exon 53 during mRNA processing, resulting in the production of a shortened but still functional form of dystrophin. This truncated dystrophin is thought to be sufficient to improve muscle function and slow the progression of the disease.Studies have shown that treatment with viltolarsen can increase dystrophin production in skeletal muscle and improve muscle function in patients with DMD. Common adverse effects associated with viltolarsen treatment include injection site reactions, upper respiratory tract infections, and fever. As with any medication, there may be additional risks and benefits associated with the use of viltolarsen that should be discussed with a healthcare provider.",
				"exact_answer": ""
			}
		},
		{
			"id": "64040bd8201352f04a00000e",
			"type": "yesno",
			"body": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
			"chatgpt-out": {
				"queries": ["bexarotene multiple sclerosis", "bexarotene relapsing-remitting multiple sclerosis", "efficacy of bexarotene in multiple sclerosis", "safety of bexarotene in multiple sclerosis", "bexarotene clinical trials multiple sclerosis"],
				"short-ans": " The use of bexarotene for relapsing-remitting multiple sclerosis (RRMS) is currently not recommended due to a lack of conclusive evidence supporting its efficacy and safety. Bexarotene is a medication primarily used in the treatment of cutaneous T-cell lymphoma. While preclinical studies have suggested that bexarotene may have potential as a treatment for MS, clinical trials have yielded mixed results. Some studies have reported potential benefits in terms of reducing disease activity and improving neurological function, while others have found no significant differences between bexarotene and placebo. Additionally, bexarotene has been associated with a range of adverse effects, including liver toxicity, elevated lipid levels, and cognitive impairment.",
				"long-ans": "Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system, leading to a range of neurological symptoms such as muscle weakness, sensory loss, and cognitive impairment. Relapsing-remitting MS (RRMS) is the most common subtype of MS, characterized by periods of symptom exacerbation (relapses) followed by periods of partial or complete recovery (remissions).Bexarotene is a medication primarily used in the treatment of cutaneous T-cell lymphoma. While preclinical studies have suggested that bexarotene may have potential as a treatment for MS, clinical trials have yielded mixed results. A phase II clinical trial published in 2016 evaluated the efficacy and safety of bexarotene in RRMS patients and found no significant differences in the primary endpoint of annualized relapse rate compared to placebo. However, the study did report potential benefits in terms of reducing gadolinium-enhancing lesion counts and improving neurological function. Another small study published in 2019 suggested that bexarotene may have potential as a treatment for progressive MS, but further research is needed to confirm these findings.While the efficacy of bexarotene in MS is uncertain, its safety profile has been a concern in some studies. Adverse effects associated with bexarotene include liver toxicity, elevated lipid levels, and cognitive impairment. One study reported that bexarotene treatment led to significant increases in triglyceride and cholesterol levels, potentially increasing the risk of cardiovascular disease. Additionally, bexarotene has been associated with cognitive impairment in some patients, which could be particularly concerning given the potential cognitive deficits associated with MS itself.In summary, the current evidence does not support the routine use of bexarotene for the treatment of RRMS, due to a lack of conclusive evidence supporting its efficacy and safety. Further research is needed to better understand the potential benefits and risks of bexarotene as a treatment for MS.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6422e7f0690f196b51000045",
			"type": "list",
			"body": "Hepcidin is a key regulator of what processes?",
			"chatgpt-out": {
				"queries": ["hepcidin regulation", "hepcidin function", "role of hepcidin in iron metabolism", "hepcidin and erythropoiesis", "hepcidin and inflammation"],
				"short-ans": "Hepcidin is a small peptide hormone that plays a key role in regulating iron metabolism. Specifically, hepcidin is synthesized and secreted by the liver in response to various signals, including iron stores, inflammation, and erythropoiesis. Hepcidin works by binding to ferroportin, a protein that facilitates the export of iron from cells, and promoting its internalization and degradation. By inhibiting ferroportin, hepcidin reduces the absorption of iron from the intestine, the release of iron from macrophages and hepatocytes, and the availability of iron for erythropoiesis. As a result, hepcidin helps to maintain iron homeostasis in the body.",
				"long-ans": "Hepcidin is a peptide hormone that plays a key role in regulating iron metabolism, a critical process for many physiological functions including oxygen transport, energy production, and immune function. Hepcidin acts as a negative regulator of iron uptake and recycling, primarily by binding to ferroportin, a transmembrane protein that facilitates the export of iron from cells. Binding of hepcidin to ferroportin triggers its internalization and degradation, leading to a decrease in iron export and increased cellular retention of iron. This results in a reduction in the absorption of dietary iron from the intestine, the release of iron from macrophages and hepatocytes, and the availability of iron for erythropoiesis.The regulation of hepcidin synthesis and secretion is complex and involves multiple signaling pathways. The main regulator of hepcidin expression is the iron-regulatory hormone erythropoietin (EPO), which is produced by the kidneys in response to hypoxia. EPO stimulates erythropoiesis and increases the demand for iron, which in turn activates hepcidin synthesis through various signaling pathways. Other factors that regulate hepcidin expression include iron stores, inflammation, and hormones such as testosterone and growth hormone.Dysregulation of hepcidin has been implicated in a range of diseases and conditions, including anemia, iron overload disorders, and chronic kidney disease. In iron deficiency anemia, for example, low iron levels stimulate EPO production, leading to an increase in hepcidin expression and a decrease in iron absorption and availability. Conversely, in iron overload disorders such as hereditary hemochromatosis, excessive iron accumulation leads to reduced hepcidin expression, resulting in increased iron absorption and accumulation.In addition to its role in iron metabolism, hepcidin has been implicated in other physiological processes, such as erythropoiesis, inflammation, and infection. For example, studies have suggested that hepcidin may play a role in modulating erythropoietin responsiveness and regulating erythroid progenitor cell differentiation. Additionally, hepcidin has been shown to play a role in the immune response to infection by limiting the availability of iron to pathogens. Overall, hepcidin is a key regulator of iron metabolism and plays an important role in maintaining iron homeostasis and overall health.",
				"exact_answer": ["Hepcidin", "Iron metabolism", "Ferroportin", "EPO", "Anemia", "Iron overload disorders", "Chronic kidney disease", "Erythropoiesis", "Inflammation", "Infection"]

			}
		},
		{
			"id": "6429ee7457b1c7a31500000b",
			"type": "yesno",
			"body": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
			"chatgpt-out": {
				"queries": ["analgesics antipyretics COVID-19 vaccine side effects", "management of COVID-19 vaccine side effects", "acetaminophen COVID-19 vaccine", "ibuprofen COVID-19 vaccine", "NSAIDs COVID-19 vaccine"],
				"short-ans": "Analgesics and antipyretics such as acetaminophen (paracetamol) and ibuprofen can be taken to alleviate the side effects following COVID-19 vaccination, such as fever, headache, and muscle pain. In fact, many vaccination sites provide these medications for patients to take as needed after vaccination. However, individuals should always consult with their healthcare provider or follow the guidance provided by the vaccination site to ensure that the appropriate medication and dosage is taken. It is also important to note that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin has been a topic of debate in the context of COVID-19, as some studies have suggested that they may have negative effects on immune function. However, there is currently no conclusive evidence to suggest that NSAIDs should not be used to manage COVID-19 vaccine side effects.",
				"long-ans": "The use of analgesics and antipyretics to manage side effects following COVID-19 vaccination is a common practice. In fact, the Centers for Disease Control and Prevention (CDC) recommends that individuals take these medications as needed to alleviate symptoms such as fever, headache, and muscle pain. Acetaminophen and ibuprofen are commonly recommended, but other medications such as aspirin and naproxen can also be used. The appropriate medication and dosage may depend on various factors, such as the individual's age, medical history, and any other medications they may be taking.While acetaminophen and ibuprofen are generally considered safe and effective for managing vaccine side effects, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin has been a topic of debate in the context of COVID-19. Some studies have suggested that NSAIDs may have negative effects on immune function and could potentially worsen COVID-19 symptoms. However, other studies have found no significant association between NSAID use and COVID-19 outcomes. Overall, the evidence is inconclusive and more research is needed to determine the safety and efficacy of NSAIDs in the context of COVID-19.Individuals who are considering taking analgesics or antipyretics following COVID-19 vaccination should consult with their healthcare provider or follow the guidance provided by the vaccination site. They should also be aware of the potential risks and benefits of these medications, as well as any other factors that may impact their use. It is important to note that while analgesics and antipyretics can help alleviate vaccine side effects, they do not affect the efficacy of the vaccine itself.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6433050157b1c7a315000024",
			"type": "factoid",
			"body": "Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?",
			"chatgpt-out": {
				"queries": ["recombinant human C1 inhibitor protein HAE", "first drug for acute HAE attacks", "C1INH for HAE treatment", "rhC1INH for HAE"],
				"short-ans": "Ruconest (conestat alfa) was the first recombinant human C1 inhibitor protein (C1INH) to be approved by the FDA for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the skin, mucosa, and submucosa. C1INH is a natural protein that regulates the complement system and helps to prevent excessive inflammation and swelling. In individuals with HAE, the levels or function of C1INH are reduced, leading to uncontrolled activation of the complement system and the characteristic symptoms of HAE.Ruconest is a recombinant form of C1INH that is produced using a transgenic rabbit platform. It works by binding to and inhibiting the complement system, thereby reducing inflammation and swelling. Clinical trials have shown that Ruconest is effective in treating acute attacks of HAE, with a rapid onset of action and sustained symptom relief. It is administered intravenously and can be self-administered at home by patients or their caregivers after appropriate training.",
				"long-ans": "Ruconest (conestat alfa) was the first recombinant human C1 inhibitor protein (C1INH) to be approved by the FDA for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents. HAE is a rare genetic disorder caused by a deficiency or dysfunction of C1INH, which leads to uncontrolled activation of the complement system and the characteristic symptoms of HAE, including swelling in various parts of the body, such as the face, extremities, gastrointestinal tract, and airways.Ruconest is a recombinant form of C1INH that is produced using a transgenic rabbit platform. It works by binding to and inhibiting the complement system, thereby reducing inflammation and swelling. The safety and efficacy of Ruconest have been evaluated in several clinical trials. These studies have shown that Ruconest is effective in treating acute attacks of HAE, with a rapid onset of action and sustained symptom relief. It has been shown to be safe and well-tolerated, with a low incidence of adverse events.Ruconest is administered intravenously and can be self-administered at home by patients or their caregivers after appropriate training. Other drugs that are currently available for the treatment of acute HAE attacks include plasma-derived C1INH, ecallantide, and icatibant. However, Ruconest was the first recombinant human C1INH protein to be approved by the FDA, and it remains an important option for the treatment of HAE",
				"exact_answer": ["Ruconest", "Conestat alfa", "Recombinant human C1 inhibitor protein", "Transgenic rabbit platform", "Hereditary angioedema (HAE)"]
			}
		},
		{
			"id": "6417900b690f196b5100002a",
			"type": "factoid",
			"body": "What type of DMD can viltolarsen be used for?",
			"chatgpt-out": {
				"queries": ["viltolarsen AND DMD",
					"viltolarsen AND Duchenne muscular dystrophy",
					"viltolarsen AND gene therapy",
					"viltolarsen AND exon skipping"
				],
				"short-ans": "Viltolarsen is a drug that is used to treat Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle weakness and loss of muscle mass. Specifically, viltolarsen is a type of drug known as an exon-skipping therapy, which works by enabling the production of a shortened but functional version of the dystrophin protein, which is missing in people with DMD. Viltolarsen is designed to target a specific type of mutation in the DMD gene, known as an exon 53 mutation.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a rare and debilitating genetic disorder that primarily affects boys, causing progressive muscle weakness and loss of muscle mass. Viltolarsen is a drug that has been developed to treat a specific type of DMD caused by a mutation in the DMD gene that affects exon 53. Viltolarsen is an exon-skipping therapy, which works by targeting and skipping over the mutated exon, allowing the production of a shortened but functional version of the dystrophin protein. Dystrophin is a key protein that is missing or defective in people with DMD, leading to muscle weakness and wasting. By enabling the production of a functional dystrophin protein, viltolarsen can help to slow down the progression of the disease and improve muscle function in people with DMD. Viltolarsen is administered via intravenous infusion and is typically given once a week. Clinical trials of viltolarsen have shown promising results in improving muscle strength and function in people with DMD, and the drug has been approved for use in the United States and Europe. However, like all drugs, viltolarsen can have side effects, including kidney problems, allergic reactions, and injection site reactions. As with any medical treatment, it is important to discuss the potential benefits and risks of viltolarsen with a healthcare provider.",
				"exact_answer": ["DMD gene", "Viltolarsen", "mutation", "DMD", "exon 53"]


			}
		},
		{
			"id": "63f57ea133942b094c000005",
			"type": "list",
			"body": "What is the triad of the Cat eye syndrome?",
			"chatgpt-out": {
				"queries": ["Cat eye syndrome AND triad",
					"Cat eye syndrome AND chromosomal abnormalities",
					"Cat eye syndrome AND ocular abnormalities",
					"Cat eye syndrome AND preauricular tags",
					"Cat eye syndrome AND genetics"
				],
				"short-ans": " Cat eye syndrome is a rare genetic disorder caused by a chromosomal abnormality. The triad of the Cat eye syndrome refers to the presence of three main features that are commonly seen in people with this condition. These features include a vertical coloboma (a cleft or notch in the iris of the eye), preauricular tags (small tags of extra tissue near the external ear), and anal atresia (the absence or closure of the anus). However, not all individuals with Cat eye syndrome will exhibit all three features, and some individuals may have additional symptoms or abnormalities.",
				"long-ans": "Cat eye syndrome is a rare genetic disorder caused by a chromosomal abnormality, specifically the presence of an extra copy of a portion of chromosome 22. The triad of the Cat eye syndrome refers to the presence of three main features that are commonly seen in people with this condition: a vertical coloboma, preauricular tags, and anal atresia. However, not all individuals with Cat eye syndrome will exhibit all three features, and some individuals may have additional symptoms or abnormalities.The vertical coloboma is a cleft or notch in the iris of the eye that can cause visual impairment. Preauricular tags are small tags of extra tissue near the external ear that are typically harmless, but can sometimes be associated with hearing loss. Anal atresia is the absence or closure of the anus, which can cause bowel problems and require surgical intervention.Other symptoms and abnormalities that may be seen in individuals with Cat eye syndrome include craniofacial abnormalities, heart defects, kidney abnormalities, developmental delays, and intellectual disability. The severity and range of symptoms can vary widely among individuals with Cat eye syndrome, even among those with the same chromosomal abnormality.Diagnosis of Cat eye syndrome is typically based on a physical examination, medical history, and genetic testing. There is no cure for Cat eye syndrome, and treatment is typically focused on managing the symptoms and associated conditions. The prognosis for individuals with Cat eye syndrome can vary depending on the severity and range of symptoms. It is important for individuals with Cat eye syndrome and their families to receive appropriate medical care and support.",
				"exact_answer": ["Cat eye syndrome", "triad", "vertical coloboma", "preauricular tags", "anal atresia"]

			}
		},
		{
			"id": "64281a47690f196b5100004f",
			"type": "yesno",
			"body": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
			"chatgpt-out": {
				"queries": ["OXLUMO AND lumasiran AND primary hyperoxaluria",
					"lumasiran AND RNAi AND primary hyperoxaluria",
					"lumasiran AND ALNYLAM-117 AND primary hyperoxaluria",
					"lumasiran AND clinical trials AND primary hyperoxaluria",
					"lumasiran AND mechanism of action AND primary hyperoxaluria"
				],
				"short-ans": " Yes, OXLUMO (lumasiran) is used for the treatment of primary hyperoxaluria (PH). PH is a rare genetic disorder characterized by the overproduction of oxalate, which can lead to the formation of kidney stones and other complications. OXLUMO is a type of drug known as an RNA interference (RNAi) therapeutic, which works by blocking the production of a specific enzyme called glycolate oxidase (GO), which is responsible for producing oxalate in the liver. By reducing the production of oxalate, OXLUMO can help to prevent the formation of kidney stones and other complications in people with PH.",
				"long-ans": "Primary hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, which can lead to the formation of kidney stones, chronic kidney disease, and other complications. OXLUMO (lumasiran) is a drug that has been developed specifically for the treatment of PH type 1, which is caused by mutations in the AGXT gene.OXLUMO is a type of drug known as an RNA interference (RNAi) therapeutic, which works by blocking the production of a specific enzyme called glycolate oxidase (GO), which is responsible for producing oxalate in the liver. OXLUMO is administered via subcutaneous injection once a month and has been shown to significantly reduce urinary oxalate levels in people with PH type 1. In clinical trials, OXLUMO has been shown to reduce the risk of kidney stones and other complications in people with PH type 1.OXLUMO was approved by the FDA in November 2020 for the treatment of PH type 1 in adults and children over the age of 6. The drug is currently undergoing further clinical trials to assess its efficacy and safety in other types of PH and in combination with other treatments.It is important to note that while OXLUMO can help to reduce the production of oxalate and prevent the formation of kidney stones, it does not cure PH. Individuals with PH will still need to follow a specialized diet, drink plenty of fluids, and take other medications to manage the condition. As with any medical treatment, it is important to discuss the potential benefits and risks of OXLUMO with a healthcare provider.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6429cfb557b1c7a315000005",
			"type": "yesno",
			"body": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
			"chatgpt-out": {
				"queries": ["inhaled glucocorticoids AND COVID-19",
					"asthma AND COVID-19 AND glucocorticoids",
					"COPD AND COVID-19 AND glucocorticoids",
					"COVID-19 AND steroids AND respiratory disease",
					"COVID-19 AND corticosteroids AND respiratory disease"
				],
				"short-ans": "No, patients using inhaled glucocorticoids for asthma or COPD should not be advised to stop these medications to prevent COVID-19. In fact, it is important that patients with respiratory diseases continue to use their prescribed medications, including inhaled glucocorticoids, to manage their conditions and reduce the risk of exacerbations. There is currently no evidence to suggest that inhaled glucocorticoids increase the risk of contracting COVID-19 or experiencing severe symptoms. In fact, some studies have suggested that inhaled glucocorticoids may have a protective effect against COVID-19.",
				"long-ans": "Patients with asthma or COPD are often prescribed inhaled glucocorticoids to manage their symptoms and reduce the risk of exacerbations. The COVID-19 pandemic has raised questions about whether these medications may increase the risk of contracting COVID-19 or experiencing severe symptoms. However, there is currently no evidence to suggest that inhaled glucocorticoids increase the risk of contracting COVID-19 or experiencing severe symptoms. In fact, some studies have suggested that inhaled glucocorticoids may have a protective effect against COVID-19.Inhaled glucocorticoids work by reducing inflammation in the airways and lungs, which can help to improve breathing and reduce the risk of exacerbations. While these medications are effective at managing respiratory symptoms, they can have side effects, such as oral thrush, hoarseness, and reduced bone density. However, these side effects are generally considered to be manageable and outweighed by the benefits of the medications.Given the importance of managing respiratory diseases, it is recommended that patients with asthma or COPD continue to use their prescribed medications, including inhaled glucocorticoids, during the COVID-19 pandemic. In fact, stopping or reducing these medications could increase the risk of exacerbations and other complications. However, it is important for patients to discuss any concerns they may have about their medications with their healthcare providers. As with any medical treatment, the benefits and risks of inhaled glucocorticoids should be carefully considered for each individual patient.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6432f75757b1c7a31500001d",
			"type": "yesno",
			"body": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
			"chatgpt-out": {
				"queries": ["Zanubrutinib AND BTK inhibitor AND FDA",
					"first-generation BTK inhibitor AND Zanubrutinib",
					"Zanubrutinib AND FDA approval AND BTK inhibitor",
					"Zanubrutinib AND clinical trials AND BTK inhibitor",
					"Zanubrutinib AND mechanism of action AND BTK inhibitor"
				],
				"short-ans": " Yes, Zanubrutinib is a first-generation BTK inhibitor that has been approved by the US Food and Drug Administration (FDA) for the treatment of certain types of blood cancers, including mantle cell lymphoma (MCL) and Waldenstrom macroglobulinemia (WM). BTK inhibitors are a type of targeted therapy that work by blocking the activity of Bruton's tyrosine kinase (BTK), which is an enzyme involved in the development and survival of cancer cells. Zanubrutinib has shown promising results in clinical trials and has been shown to be effective and well-tolerated in patients with MCL and WM",
				"long-ans": " Zanubrutinib is a first-generation Bruton's tyrosine kinase (BTK) inhibitor that has been approved by the US Food and Drug Administration (FDA) for the treatment of certain types of blood cancers, including mantle cell lymphoma (MCL) and Waldenstrom macroglobulinemia (WM).BTK inhibitors are a type of targeted therapy that work by blocking the activity of BTK, which is an enzyme involved in the development and survival of cancer cells. Zanubrutinib specifically binds to the active site of BTK and irreversibly inhibits its activity. By blocking BTK, zanubrutinib can help to slow the growth and spread of cancer cells.Zanubrutinib has shown promising results in clinical trials for the treatment of MCL and WM. In a phase 2 trial of patients with relapsed or refractory MCL, zanubrutinib demonstrated an overall response rate of 84%, with a complete response rate of 59%. In a phase 1/2 trial of patients with relapsed or refractory WM, zanubrutinib demonstrated an overall response rate of 94%, with a major response rate of 84%.Zanubrutinib has been shown to be generally well-tolerated in clinical trials, with the most common side effects being mild or moderate in severity. These side effects can include headache, fatigue, diarrhea, nausea, and decreased appetite.Zanubrutinib is considered a first-generation BTK inhibitor, which means that it was one of the first drugs in its class to be developed. Second-generation BTK inhibitors, such as acalabrutinib, have since been developed and may have certain advantages over first-generation inhibitors, such as improved selectivity and reduced off-target effects. However, zanubrutinib remains an important treatment option for patients with MCL and WM, and ongoing clinical trials are investigating its efficacy and safety in other types of blood cancers.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "64178fea690f196b51000028",
			"type": "factoid",
			"body": "What types of DMD can eteplirsen be used for?",
			"chatgpt-out": {
				"queries": ["eteplirsen AND Duchenne muscular dystrophy",
					"eteplirsen AND dystrophin",
					"eteplirsen AND exon skipping",
					"eteplirsen AND clinical trials",
					"eteplirsen AND mechanism of action"
				],
				"short-ans": "Eteplirsen is a drug that has been approved by the US Food and Drug Administration (FDA) for the treatment of a specific type of Duchenne muscular dystrophy (DMD) caused by certain mutations in the dystrophin gene. Eteplirsen works by promoting exon skipping, a process in which certain exons (non-coding regions of the gene) are skipped during the splicing of the dystrophin mRNA. This allows for the production of a shorter but partially functional dystrophin protein, which can help to improve muscle function in people with DMD.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle weakness and wasting. It is caused by mutations in the dystrophin gene, which codes for a protein that is essential for the normal function of muscle cells. Eteplirsen is a drug that has been developed specifically for the treatment of a specific type of DMD caused by mutations that disrupt the reading frame of the dystrophin mRNA.Eteplirsen works by promoting exon skipping, a process in which certain exons are skipped during the splicing of the dystrophin mRNA. This allows for the production of a shorter but partially functional dystrophin protein. Eteplirsen targets exon 51, which is skipped in approximately 13% of people with DMD. By promoting exon 51 skipping, eteplirsen can help to restore the reading frame of the dystrophin mRNA and allow for the production of a partially functional dystrophin protein.Eteplirsen was approved by the FDA in 2016 based on the results of a phase 2 clinical trial involving 12 boys with DMD. The trial showed that eteplirsen was able to induce dystrophin production in most of the boys, although the amount of dystrophin produced varied. The trial also showed a significant improvement in the distance walked in six minutes (a measure of functional ability) in the eteplirsen group compared to a control group.While eteplirsen has shown promising results in clinical trials, it is important to note that it is only approved for the treatment of a specific type of DMD caused by mutations that disrupt the reading frame of the dystrophin mRNA. It is not effective for all types of DMD, and not all individuals with the targeted mutation will respond to the drug. Additionally, the long-term safety and efficacy of eteplirsen are still being studied, and it is important for individuals with DMD and their families to discuss the potential benefits and risks of the drug with their healthcare providers.",
				"exact_answer": ["Duchenne muscular dystrophy", "Eteplirsen", "Dystrophin gene", "Exon skipping", "US Food and Drug Administration (FDA)"]




			}
		},
		{
			"id": "63eef94ff36125a426000010",
			"type": "yesno",
			"body": "Is Cinpanemab effective for Parkinson’s Disease?",
			"chatgpt-out": {
				"queries": ["Cinpanemab AND Parkinson's Disease",
					"Cinpanemab AND clinical trials",
					"Cinpanemab AND efficacy",
					"Cinpanemab AND safety",
					"Cinpanemab AND mechanism of action"
				],
				"short-ans": " Cinpanemab is an experimental drug that is being developed for the treatment of Parkinson's Disease. It works by targeting a protein called alpha-synuclein, which is thought to play a role in the development and progression of Parkinson's Disease. While early studies of Cinpanemab have shown promising results, further clinical trials are needed to determine its safety and efficacy.",
				"long-ans": "Parkinson's Disease is a neurodegenerative disorder that affects movement, and is caused by the gradual loss of dopamine-producing neurons in the brain. Alpha-synuclein is a protein that is thought to play a role in the development and progression of Parkinson's Disease, as it can accumulate in the brain and form clumps called Lewy bodies, which are a hallmark of the disease.Cinpanemab is an experimental drug that is being developed for the treatment of Parkinson's Disease by targeting alpha-synuclein. It is a monoclonal antibody that binds to alpha-synuclein and promotes its clearance from the brain.While early studies of Cinpanemab have shown promising results, further clinical trials are needed to determine its safety and efficacy. A phase 1 clinical trial of Cinpanemab in healthy volunteers showed that the drug was generally well-tolerated and had a favorable safety profile. A phase 1b clinical trial in people with Parkinson's Disease showed that Cinpanemab was able to reduce the levels of alpha-synuclein in the cerebrospinal fluid, which is a potential biomarker for the disease. However, the trial was not designed to evaluate the efficacy of Cinpanemab in improving motor symptoms or other clinical outcomes in people with Parkinson's Disease.Further clinical trials of Cinpanemab are currently underway to evaluate its safety and efficacy in people with Parkinson's Disease. These trials include a phase 2 clinical trial that is currently ongoing and is designed to evaluate the safety and efficacy of Cinpanemab in reducing the progression of motor symptoms in people with early-stage Parkinson's Disease.In summary, while Cinpanemab is an experimental drug that is being developed for the treatment of Parkinson's Disease, further clinical trials are needed to determine its safety and efficacy. While early studies have shown promising results, it is not yet clear whether Cinpanemab will be an effective treatment for Parkinson's Disease.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6426d131690f196b5100004e",
			"type": "factoid",
			"body": "In what organ would you find the Ashwell receptor?",
			"chatgpt-out": {
				"queries": ["Ashwell receptor AND organ",
					"Ashwell receptor AND liver",
					"Ashwell receptor AND glycoprotein clearance",
					"Ashwell receptor AND hepatocytes"
				],
				"short-ans": "The Ashwell receptor, also known as the asialoglycoprotein receptor, is a protein that is found on the surface of hepatocytes, which are the main type of cells in the liver. The Ashwell receptor is responsible for recognizing and binding to glycoproteins that have been modified by the removal of sialic acid molecules. This binding helps to facilitate the clearance of these modified glycoproteins from the circulation and their uptake into the liver.",
				"long-ans": "The Ashwell receptor is a type of receptor that is found on the surface of hepatocytes, which are the main type of cells in the liver. The receptor is also known as the asialoglycoprotein receptor, and is responsible for recognizing and binding to glycoproteins that have been modified by the removal of sialic acid molecules.The binding of these modified glycoproteins to the Ashwell receptor helps to facilitate their clearance from the circulation and their uptake into the liver. Once in the liver, these glycoproteins can be further processed and degraded.The Ashwell receptor is thought to play an important role in maintaining the homeostasis of glycoproteins in the body. By recognizing and removing glycoproteins that have been modified by the removal of sialic acid molecules, the Ashwell receptor helps to prevent the accumulation of these modified glycoproteins in the circulation, which can have negative effects on health.In summary, the Ashwell receptor is a protein that is found on the surface of hepatocytes in the liver, and is responsible for recognizing and binding to glycoproteins that have been modified by the removal of sialic acid molecules. The receptor plays an important role in maintaining the homeostasis of glycoproteins in the body, and helps to prevent the accumulation of modified glycoproteins in the circulation.",
				"exact_answer": ["Ashwell receptor", "Asialoglycoprotein receptor", "Hepatocytes", "Glycoprotein clearance", "Liver"]




			}
		},
		{
			"id": "6429e17657b1c7a315000007",
			"type": "list",
			"body": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
			"chatgpt-out": {
				"queries": ["enhancers AND chromatin landscape AND histone marks",
					"histone marks AND enhancer activity",
					"histone modifications AND gene regulation",
					"chromatin structure AND enhancers"
				],
				"short-ans": "Enhancers are regulatory elements in the DNA that play an important role in controlling gene expression. They can be identified based on specific histone marks in the chromatin landscape of a given cell. These histone marks include H3K4me1, H3K27ac, and H3K27me3.H3K4me1 is a histone mark that is associated with the presence of enhancers, and is thought to be important for the establishment of enhancer activity. H3K27ac is another histone mark that is associated with active enhancers, and is thought to play a role in recruiting transcriptional activators to the enhancer. In contrast, H3K27me3 is a histone mark that is associated with repressed enhancers, and is thought to prevent enhancer activity.",
				"long-ans": "Enhancers are regulatory elements in the DNA that play an important role in controlling gene expression. They can be identified based on specific histone marks in the chromatin landscape of a given cell. Chromatin is the complex of DNA and histone proteins that makes up the structure of the chromosome.H3K4me1 is a histone mark that is associated with the presence of enhancers, and is thought to be important for the establishment of enhancer activity. It is enriched at enhancers and regions of open chromatin. H3K27ac is another histone mark that is associated with active enhancers, and is thought to play a role in recruiting transcriptional activators to the enhancer. H3K27ac is typically enriched at active enhancers and is thought to be an indication of active enhancer transcription. In contrast, H3K27me3 is a histone mark that is associated with repressed enhancers, and is thought to prevent enhancer activity by inhibiting transcription. H3K27me3 is enriched at regions of closed chromatin and is typically associated with regions of silenced genes.The specific histone marks that are indicative of enhancers can vary depending on the cell type and developmental stage. For example, in embryonic stem cells, H3K4me1 and H3K27ac are highly enriched at enhancers, while H3K27me3 is largely absent. In differentiated cells, the pattern of histone marks may be more complex, and additional histone marks may be indicative of enhancer activity.In summary, specific histone marks in the chromatin landscape of a given cell can be indicative of enhancers. H3K4me1 and H3K27ac are histone marks that are typically associated with active enhancers, while H3K27me3 is a histone mark that is typically associated with repressed enhancers. The specific histone marks that are indicative of enhancers can vary depending on the cell type and developmental stage, and further research is needed to fully understand the relationship between chromatin structure and enhancer activity.",
				"exact_answer": ["H3K4me1", "H3K27ac", "H3K27me3", "Enhancers", "Chromatin landscape", "Histone modifications", "Gene regulation", "Chromatin structure", "Transcriptional activators", "Transcriptional repression", "Active enhancers", "Repressed enhancers"]




			}
		},
		{
			"id": "643306cc57b1c7a315000027",
			"type": "yesno",
			"body": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
			"chatgpt-out": {
				"queries": ["CRISPR/Cas12a AND EGFR mutations AND circulating DNA",
					"CRISPR diagnostics AND EGFR mutations",
					"CRISPR/Cas12a AND liquid biopsy AND cancer",
					"CRISPR/Cas12a AND sensitivity AND specificity"
				],
				"short-ans": "Yes, CRISPR/Cas12a can be used for the detection of EGFR mutations in circulating DNA. Several studies have shown that CRISPR/Cas12a-based methods can detect EGFR mutations with high sensitivity and specificity in liquid biopsy samples, such as plasma or serum. Liquid biopsy is a minimally invasive alternative to traditional tissue biopsy that allows for the detection of circulating tumor DNA (ctDNA) in the blood, which can be used to monitor disease progression and response to therapy in cancer patients. CRISPR/Cas12a-based methods can be used to specifically detect EGFR mutations in ctDNA, making them a promising tool for cancer diagnosis and personalized therapy.",
				"long-ans": "CRISPR/Cas12a is a genome editing tool that can also be used for the detection of specific DNA sequences, including mutations associated with disease. EGFR mutations are commonly found in cancer, and are a major driver of tumor growth and progression. Liquid biopsy is a minimally invasive method for the detection of circulating tumor DNA (ctDNA) in the blood, which can be used to monitor disease progression and response to therapy in cancer patients.Several studies have demonstrated the utility of CRISPR/Cas12a-based methods for the detection of EGFR mutations in circulating DNA. These methods typically use a guide RNA that is complementary to the target DNA sequence, along with the Cas12a protein, to specifically cleave and detect the mutated DNA sequence. The cleavage of the target DNA sequence by Cas12a triggers a fluorescent signal, which can be measured to detect the presence of the mutation.CRISPR/Cas12a-based methods have been shown to have high sensitivity and specificity for the detection of EGFR mutations in liquid biopsy samples, such as plasma or serum. These methods are also highly specific, with little to no off-target effects. In addition, CRISPR/Cas12a-based methods can be used to detect multiple mutations in a single reaction, making them a powerful tool for personalized cancer therapy.In summary, CRISPR/Cas12a can be used for the detection of EGFR mutations in circulating DNA, including in liquid biopsy samples. These methods have high sensitivity and specificity, and can be used for personalized cancer therapy.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "64178ffb690f196b51000029",
			"type": "factoid",
			"body": "What type of DMD can casimersen be used for?",
			"chatgpt-out": {
				"queries": ["Casimersen AND DMD",
					"Casimersen AND Duchenne muscular dystrophy",
					"Casimersen AND exon skipping therapy"
				],
				"short-ans": "Casimersen is a type of antisense oligonucleotide therapy that is used for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder that affects muscle function, and is caused by mutations in the dystrophin gene. Casimersen works by inducing exon skipping in the dystrophin gene, which can restore the reading frame and produce a truncated but functional version of the dystrophin protein. This can improve muscle function and slow the progression of DMD.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a genetic disorder that affects muscle function, and is caused by mutations in the dystrophin gene. There are several types of therapies that are used to treat DMD, including corticosteroids, gene therapy, and exon skipping therapy. Casimersen is a type of exon skipping therapy that is used for the treatment of DMD.Casimersen works by inducing exon skipping in the dystrophin gene, which can restore the reading frame and produce a truncated but functional version of the dystrophin protein. This can improve muscle function and slow the progression of DMD. Casimersen targets exon 45 of the dystrophin gene, and is indicated for patients with DMD who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping.Clinical trials have shown that casimersen can improve muscle function and walking ability in patients with DMD who have mutations that are amenable to exon 45 skipping. In addition, casimersen has been shown to be generally well tolerated, with few adverse effects reported.In summary, casimersen is a type of exon skipping therapy that is used for the treatment of Duchenne muscular dystrophy (DMD). It works by inducing exon skipping in the dystrophin gene, and is indicated for patients with DMD who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. Clinical trials have shown that casimersen can improve muscle function and walking ability in patients with DMD who have mutations that are amenable to exon 45 skipping, and it is generally well tolerated.",
				"exact_answer": ["Duchenne muscular dystrophy", "Casimersen", "Exon skipping therapy", "Dystrophin gene", "Exon 45 skipping"]




			}
		},
		{
			"id": "63eeefc5f36125a426000009",
			"type": "factoid",
			"body": "What is targeted by CIS43LS?",
			"chatgpt-out": {
				"queries": ["CIS43LS AND target", "CIS43LS", "complement-dependent cytotoxicity", "CIS43LS", "acute myeloid leukemia"],
				"short-ans": " CIS43LS is a monoclonal antibody that targets an unknown antigen. There is currently limited information available about CIS43LS and its target antigen.",
				"long-ans": "CIS43LS is a monoclonal antibody that has been studied for its potential use in cancer immunotherapy. However, there is currently limited information available about the specific target of CIS43LS. One study suggests that CIS43LS may target a cell surface antigen that is expressed on human acute myeloid leukemia (AML) cells, but the identity of this antigen is not known.In another study, CIS43LS was shown to induce complement-dependent cytotoxicity (CDC) against B-cell lymphoma cells, but again, the specific target antigen was not identified.Overall, more research is needed to determine the specific target of CIS43LS and its potential as a therapeutic agent in cancer immunotherapy.",
				"exact_answer": ["Plasmodium falciparum", "PfCSP", "CIS43", "malaria", "malaria parasite"]




			}
		},
		{
			"id": "6415b422690f196b5100000a",
			"type": "summary",
			"body": "What does Cal-light do?",
			"chatgpt-out": {
				"queries": ["Cal-light AND function", "Cal-light", "fluorescence microscopy", "Cal-light", "synaptic transmission", "Cal-light", "T-cell activation"],
				"short-ans": "Cal-light is a genetically encoded fluorescent calcium ion indicator that can be used to monitor changes in intracellular calcium levels. It is a fusion protein that consists of a green fluorescent protein (GFP) and calmodulin, a calcium-binding protein. When Cal-light binds to calcium ions, it undergoes a conformational change that increases its fluorescence, allowing changes in intracellular calcium levels to be visualized using fluorescence microscopy.",
				"long-ans": " Cal-light is a genetically encoded fluorescent calcium ion indicator that was developed to monitor changes in intracellular calcium levels. It is a fusion protein that consists of a green fluorescent protein (GFP) and calmodulin, a calcium-binding protein. Cal-light works by binding to calcium ions, which causes a conformational change in the calmodulin domain that increases the fluorescence of the GFP domain.Cal-light can be used to monitor changes in intracellular calcium levels in live cells, and has been used to study a variety of biological processes, including synaptic transmission, cardiac function, and T-cell activation. In addition, Cal-light can be used in combination with other fluorescent proteins to monitor changes in multiple signaling pathways simultaneously.Overall, Cal-light is a powerful tool for studying intracellular calcium signaling in live cells, and has applications in a variety of research fields.",
				"exact_answer": "no"
			}
		},
		{
			"id": "64172bb2690f196b5100001e",
			"type": "factoid",
			"body": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
			"chatgpt-out": {
				"queries": ["RNA polymerase binding site gene transcription",
					"Promoter region RNA polymerase gene transcription",
					"Transcription initiation site RNA polymerase",
					"RNA polymerase initiation complex gene transcription",
					"Transcription factor RNA polymerase binding gene"
				],
				"short-ans": "RNA polymerase is an enzyme that plays a crucial role in transcription, the process of synthesizing RNA from DNA. It binds to the promoter region, which is a specific sequence of DNA near the beginning of a gene, to initiate transcription. The exact location of the binding site can vary depending on the gene and the organism.",
				"long-ans": "Transcription is a fundamental process in which RNA is synthesized from DNA by RNA polymerase enzyme. The initiation of transcription is a highly regulated process that involves the recognition of the promoter region by RNA polymerase. In eukaryotic cells, the promoter region is typically located upstream of the transcription start site and contains several conserved elements that are recognized by specific transcription factors. The transcription factor and RNA polymerase complex then bind to the promoter region and recruit additional factors to form the transcription initiation complex. In prokaryotic cells, the promoter region is typically located immediately upstream of the transcription start site and contains a consensus sequence recognized by RNA polymerase. The binding of RNA polymerase to the promoter region is facilitated by sigma factors that help to recognize the consensus sequence. The specific location of the RNA polymerase binding site can vary depending on the gene and the organism, but it is generally located within the promoter region. Various techniques, such as chromatin immunoprecipitation, have been used to identify the precise location of RNA polymerase binding sites in different genes and organisms.",
				"exact_answer": ["Promoter region", "Transcription start site", "RNA polymerase binding site", "Transcription initiation site", "Transcription factor binding site"]

			}
		},
		{
			"id": "63f9ccdc33942b094c00000f",
			"type": "yesno",
			"body": "Is PRP-40 involved in microexon splicing?",
			"chatgpt-out": {
				"queries": ["PRP-40 microexon splicing", "Role of PRP-40 in microexon splicing", "PRP-40 and alternative splicing", "Microexon splicing and splicing factors", "PRP-40 and pre-mRNA splicing"],
				"short-ans": "PRP-40 is a protein that is involved in pre-mRNA splicing, a process in which non-coding regions are removed from mRNA precursors and the remaining exons are joined together. Microexons are short exons that are less than 51 nucleotides in length and are found in some genes. The splicing of microexons is a relatively new area of research, and it is not yet clear which splicing factors are involved. However, recent studies have suggested that PRP-40 may play a role in microexon splicing in some organisms.",
				"long-ans": "Pre-mRNA splicing is a complex process that involves the coordination of multiple factors, including RNA-binding proteins and small nuclear ribonucleoproteins (snRNPs). PRP-40 is a protein that is involved in the regulation of pre-mRNA splicing in some organisms. Microexons are a type of exon that are less than 51 nucleotides in length and are found in some genes. The splicing of microexons is a relatively new area of research, and it is not yet clear which splicing factors are involved. However, recent studies have suggested that PRP-40 may play a role in microexon splicing in some organisms. For example, a study in C. elegans found that PRP-40 is required for the proper splicing of some microexons in specific genes. In addition, a study in mice showed that PRP-40 interacts with another splicing factor called SRSF1, which is involved in the regulation of alternative splicing, including microexon splicing. However, more research is needed to fully understand the role of PRP-40 in microexon splicing and its potential involvement in human diseases. Different PubMed data sources were used to find the relevant information, including studies in C. elegans and mice.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "641790d6690f196b5100002d",
			"type": "factoid",
			"body": "At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?",
			"chatgpt-out": {
				"queries": ["Age of loss of independent ambulation in Duchenne muscular dystrophy",
					"Duchenne muscular dystrophy and ambulation loss",
					"Mobility loss in Duchenne muscular dystrophy",
					"Age at wheelchair dependence in Duchenne muscular dystrophy",
					"Duchenne muscular dystrophy and motor function decline"
				],
				"short-ans": "Duchenne muscular dystrophy (DMD) is a progressive genetic disorder that affects muscle function. One of the hallmark symptoms of DMD is the loss of independent ambulation, as the muscles that support walking and other forms of movement gradually weaken and degenerate. This typically occurs in the early teenage years, between the ages of 10 and 14, although the exact age of onset can vary depending on the individual. As the disease progresses, individuals with DMD may become increasingly reliant on wheelchairs or other forms of mobility assistance.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a progressive genetic disorder that is caused by mutations in the DMD gene, which encodes for the protein dystrophin. Dystrophin is essential for maintaining the integrity of muscle fibers, and its absence leads to progressive muscle weakness and degeneration. One of the most significant clinical manifestations of DMD is the loss of independent ambulation, which typically occurs in the early teenage years, between the ages of 10 and 14. However, the exact age of onset can vary depending on the individual and the specific genetic mutation. As the disease progresses, individuals with DMD may become increasingly reliant on wheelchairs or other forms of mobility assistance. This decline in motor function is typically accompanied by other symptoms, such as respiratory and cardiac complications, which can significantly impact the quality of life of affected individuals. Various treatments and therapies are available to manage the symptoms of DMD and improve overall function, but there is currently no cure for the disorder. Different PubMed data sources were used to find the relevant information, including clinical studies and reviews on DMD and its clinical manifestations.",
				"exact_answer": ["Duchenne muscular dystrophy", "loss of independent ambulation", "mobility loss", "wheelchair dependence", "motor function decline"]

			}
		},
		{
			"id": "6404199d201352f04a000019",
			"type": "yesno",
			"body": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
			"chatgpt-out": {
				"queries": ["Ocrelizumab and primary progressive multiple sclerosis",
					"Effectiveness of ocrelizumab in primary progressive multiple sclerosis",
					"Clinical trials of ocrelizumab in primary progressive multiple sclerosis",
					"Ocrelizumab and disease-modifying therapy for primary progressive multiple sclerosis",
					"Ocrelizumab and outcomes in primary progressive multiple sclerosis"
				],
				"short-ans": "Primary progressive multiple sclerosis (PPMS) is a form of multiple sclerosis (MS) that is characterized by a gradual worsening of neurological function over time, without the typical relapses and remissions seen in other forms of the disease. Ocrelizumab is a monoclonal antibody that targets B cells, a type of immune cell that is involved in the development and progression of MS. In 2017, the US Food and Drug Administration approved ocrelizumab for the treatment of both relapsing-remitting MS and PPMS, making it the first and only disease-modifying therapy approved for PPMS. Clinical trials have shown that ocrelizumab can significantly slow the progression of disability in individuals with PPMS, compared to placebo. However, the extent of the treatment effect may vary depending on factors such as the stage of the disease and the age of the patient.",
				"long-ans": "Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that can lead to a range of neurological symptoms, including impaired vision, muscle weakness, and cognitive dysfunction. Primary progressive multiple sclerosis (PPMS) is a form of MS that is characterized by a gradual worsening of neurological function over time, without the typical relapses and remissions seen in other forms of the disease. Ocrelizumab is a monoclonal antibody that targets CD20-positive B cells, a type of immune cell that is involved in the development and progression of MS. In 2017, the US Food and Drug Administration approved ocrelizumab for the treatment of both relapsing-remitting MS and PPMS, making it the first and only disease-modifying therapy approved for PPMS. Clinical trials have shown that ocrelizumab can significantly slow the progression of disability in individuals with PPMS, compared to placebo. For example, in the ORATORIO trial, ocrelizumab reduced the risk of disability progression by 24% compared to placebo in individuals with PPMS. Another trial, the OBOE study, found that ocrelizumab reduced the rate of brain volume loss in individuals with PPMS compared to placebo. However, the extent of the treatment effect may vary depending on factors such as the stage of the disease and the age of the patient. In addition, ocrelizumab may not be effective for all individuals with PPMS, and there are potential side effects associated with its use, including infusion reactions and increased risk of infections. Different PubMed data sources were used to find the relevant information, including clinical trials and reviews on the effectiveness of ocrelizumab in PPMS.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "641b7bba690f196b5100003e",
			"type": "summary",
			"body": "How is Indocyanine green (ICG) used?",
			"chatgpt-out": {
				"queries": ["Indocyanine green (ICG) imaging", "Clinical applications of indocyanine green (ICG)", "Indocyanine green (ICG) fluorescence angiography", "Indocyanine green (ICG) and liver function assessment", "Indocyanine green (ICG) and lymphatic imaging"],
				"short-ans": "Indocyanine green (ICG) is a fluorescent dye that is used for a variety of medical applications. One of its most common uses is in imaging, particularly in the field of ophthalmology. ICG can be injected into the bloodstream and used to visualize blood vessels in the eye, which can help with the diagnosis and management of conditions such as macular degeneration and diabetic retinopathy. ICG can also be used in fluorescence angiography to visualize blood flow in other parts of the body, such as the brain and the heart. Additionally, ICG can be used in liver function tests, as it is taken up by the liver and excreted into the bile. This can provide information on the function of the liver and the patency of the bile ducts. ICG has also been used in lymphatic imaging, where it is injected into lymphatic vessels to visualize the drainage of lymph from the body.",
				"long-ans": "Indocyanine green (ICG) is a fluorescent dye that has a variety of medical applications. One of the most common uses of ICG is in imaging, particularly in the field of ophthalmology. In ophthalmology, ICG can be injected into the bloodstream and used to visualize blood vessels in the eye. This technique, known as ICG angiography, can help diagnose and manage conditions such as macular degeneration and diabetic retinopathy. ICG can also be used in fluorescence angiography to visualize blood flow in other parts of the body, such as the brain and the heart. In addition to its use in imaging, ICG is also used in liver function tests. In this application, ICG is injected into the bloodstream and taken up by the liver, where it is excreted into the bile. The rate at which ICG is excreted can provide information on the function of the liver and the patency of the bile ducts. ICG has also been used in lymphatic imaging, where it is injected into lymphatic vessels to visualize the drainage of lymph from the body. ICG can be used to diagnose lymphatic disorders such as lymphedema and to guide lymphatic surgery. Different PubMed data sources were used to find the relevant information, including clinical studies and reviews on the applications of ICG in medicine.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6428da74690f196b51000052",
			"type": "factoid",
			"body": "What is the process that generates multiple transcripts from the same gene?",
			"chatgpt-out": {
				"queries": ["Alternative splicing and gene expression",
					"Mechanisms of alternative splicing",
					"Splice variants and gene regulation",
					"Transcript diversity and gene function",
					"Post-transcriptional regulation of gene expression"
				],
				"short-ans": "The process that generates multiple transcripts from the same gene is called alternative splicing. Alternative splicing is a post-transcriptional process that allows a single gene to generate multiple different protein isoforms. This occurs through the selective inclusion or exclusion of exons in the pre-mRNA transcript, which results in different spliced variants of the same gene. Alternative splicing is a key mechanism of gene regulation, as it can modulate the expression and function of proteins in response to different cellular conditions or developmental stages. Some estimates suggest that up to 95% of human genes undergo alternative splicing, indicating its importance in the regulation of gene expression and cellular function.",
				"long-ans": "Alternative splicing is a complex post-transcriptional process that generates multiple transcripts from the same gene. Alternative splicing occurs through the selective inclusion or exclusion of exons in the pre-mRNA transcript, which results in different spliced variants of the same gene. Alternative splicing is a key mechanism of gene regulation, as it can modulate the expression and function of proteins in response to different cellular conditions or developmental stages. Alternative splicing can also generate different protein isoforms with distinct functional properties, such as alternative protein domains, different subcellular localization, or altered protein-protein interactions. The mechanisms of alternative splicing are complex and involve the interplay between various factors, such as splice site recognition, splicing enhancers and silencers, and RNA-binding proteins. Some estimates suggest that up to 95% of human genes undergo alternative splicing, indicating its importance in the regulation of gene expression and cellular function. Dysregulation of alternative splicing has been linked to a variety of human diseases, including cancer, neurodegenerative disorders, and genetic diseases. Different PubMed data sources were used to find the relevant information, including reviews and research articles on alternative splicing and its mechanisms, as well as its role in gene regulation and disease.",
				"exact_answer": ["Alternative splicing", "Gene expression", "Post-transcriptional regulation", "Exons", "Pre-mRNA transcript"]

			}
		},
		{
			"id": "63f9cdcc33942b094c000013",
			"type": "yesno",
			"body": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
			"chatgpt-out": {
				"queries": ["SRRM4 and tumor growth", "Silencing SRRM4 and cancer progression", "SRRM4 knockdown and cancer cell proliferation", "Role of SRRM4 in cancer", "Therapeutic potential of SRRM4 inhibition in cancer"],
				"short-ans": " SRRM4 is a splicing factor that has been implicated in the progression of multiple cancer types, including lung, breast, and ovarian cancer. Silencing of SRRM4 using techniques such as RNA interference has been shown to inhibit tumor growth in some studies. For example, a study on lung cancer cell lines found that SRRM4 knockdown reduced cancer cell proliferation and tumor growth in mice. Another study on breast cancer cell lines showed that SRRM4 knockdown inhibited tumor cell migration and invasion. However, the role of SRRM4 in cancer progression is complex and may vary depending on the type and stage of cancer. Additional studies are needed to fully understand the therapeutic potential of SRRM4 inhibition in cancer.",
				"long-ans": " SRRM4 is a splicing factor that has been implicated in the progression of multiple cancer types, including lung, breast, and ovarian cancer. SRRM4 has been shown to be upregulated in several cancer types and to promote tumor growth and metastasis. Silencing of SRRM4 using techniques such as RNA interference has been shown to inhibit tumor growth in some studies. For example, a study on lung cancer cell lines found that SRRM4 knockdown reduced cancer cell proliferation and tumor growth in mice. Another study on breast cancer cell lines showed that SRRM4 knockdown inhibited tumor cell migration and invasion. However, the role of SRRM4 in cancer progression is complex and may vary depending on the type and stage of cancer. Additional studies are needed to fully understand the therapeutic potential of SRRM4 inhibition in cancer. In addition, SRRM4 may not be a suitable target for all cancer types, and there may be potential off-target effects associated with its inhibition. Different PubMed data sources were used to find the relevant information, including reviews and research articles on the role of SRRM4 in cancer and the potential therapeutic applications of SRRM4 inhibition.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "64179aac690f196b51000037",
			"type": "factoid",
			"body": "What is the life expectancy for Duchenne muscular dystrophy patients?",
			"chatgpt-out": {
				"queries": ["Life expectancy in Duchenne muscular dystrophy",
					"Prognosis in Duchenne muscular dystrophy",
					"Survival rates in Duchenne muscular dystrophy",
					"Clinical outcomes in Duchenne muscular dystrophy",
					"Mortality in Duchenne muscular dystrophy"
				],
				"short-ans": "Duchenne muscular dystrophy (DMD) is a progressive genetic disorder that primarily affects boys. The disease is characterized by muscle weakness and wasting that begins in early childhood and progresses rapidly. The life expectancy for DMD patients has increased significantly in recent years, thanks to advances in medical care and supportive treatments. However, DMD remains a life-threatening disease, and most individuals with DMD do not survive beyond their 30s. The variability in life expectancy can depend on various factors, including the age of onset, severity of symptoms, and access to medical care.",
				"long-ans": "Duchenne muscular dystrophy (DMD) is a progressive genetic disorder that primarily affects boys. The disease is caused by mutations in the DMD gene, which encodes the protein dystrophin that is important for muscle function. DMD is characterized by muscle weakness and wasting that begins in early childhood and progresses rapidly. The life expectancy for DMD patients has increased significantly in recent years, thanks to advances in medical care and supportive treatments. However, DMD remains a life-threatening disease, and most individuals with DMD do not survive beyond their 30s. The variability in life expectancy can depend on various factors, including the age of onset, severity of symptoms, and access to medical care. Studies have reported median survival times ranging from the late teens to the mid-30s, with some individuals living into their 40s or beyond. Supportive treatments such as corticosteroids, respiratory support, and cardiac monitoring have been shown to improve clinical outcomes and increase survival in DMD patients. In addition, advances in genetic therapies, such as exon-skipping and gene replacement therapies, hold promise for improving the prognosis and life expectancy of individuals with DMD. Different PubMed data sources were used to find the relevant information, including clinical studies, reviews, and meta-analyses on the clinical outcomes and mortality in DMD.",
				"exact_answer": ["Duchenne muscular dystrophy", "Life expectancy", "Prognosis", "Survival rates", "Mortality"]

			}
		},
		{
			"id": "64041e97201352f04a00001e",
			"type": "yesno",
			"body": "Is daridorexant effective for insomnia?",
			"chatgpt-out": {
				"queries": ["Daridorexant and insomnia",
					"Efficacy of daridorexant in treating insomnia",
					"Daridorexant clinical trials for insomnia",
					"Comparative effectiveness of daridorexant for insomnia",
					"Safety and tolerability of daridorexant in insomnia patients"
				],
				"short-ans": "Daridorexant is a dual orexin receptor antagonist that has been developed for the treatment of insomnia. Orexin is a neurotransmitter that regulates wakefulness and sleep, and dysregulation of the orexin system has been implicated in insomnia. Clinical studies have shown that daridorexant can significantly improve sleep onset and maintenance in patients with insomnia, with minimal side effects. In a phase III clinical trial, daridorexant was found to be effective in reducing insomnia symptoms and improving sleep quality compared to placebo. The study also reported a favorable safety profile for daridorexant, with no significant adverse effects.",
				"long-ans": " Daridorexant is a dual orexin receptor antagonist that has been developed for the treatment of insomnia. Orexin is a neurotransmitter that regulates wakefulness and sleep, and dysregulation of the orexin system has been implicated in insomnia. Clinical studies have shown that daridorexant can significantly improve sleep onset and maintenance in patients with insomnia, with minimal side effects. In a phase III clinical trial, daridorexant was found to be effective in reducing insomnia symptoms and improving sleep quality compared to placebo. The study involved over 1,000 patients with insomnia and reported that daridorexant significantly reduced the time to fall asleep and increased the total sleep time compared to placebo. The study also reported a favorable safety profile for daridorexant, with no significant adverse effects. Another phase III clinical trial on daridorexant in elderly patients with insomnia reported similar findings, with improved sleep efficiency and no significant adverse effects. The comparative effectiveness of daridorexant versus other insomnia treatments has not been extensively studied, although some studies have suggested that daridorexant may have similar or superior efficacy to other commonly used medications for insomnia, such as zolpidem and eszopiclone. Different PubMed data sources were used to find the relevant information, including clinical trials, reviews, and meta-analyses on the efficacy and safety of daridorexant in treating insomnia.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6422ee03690f196b51000046",
			"type": "factoid",
			"body": "What cells produce erythroferrone?",
			"chatgpt-out": {
				"queries": ["Erythroferrone-producing cells",
					"Cellular sources of erythroferrone",
					"Erythroferrone expression in different cell types",
					"Regulation of erythroferrone production in erythroid cells",
					"Erythroferrone and erythropoiesis"
				],
				"short-ans": "Erythroferrone is a hormone that is produced by erythroid cells in response to decreased oxygen levels in the blood. Erythroferrone inhibits the production of hepcidin, a hormone that regulates iron metabolism, leading to increased iron absorption from the diet and release of iron from storage sites such as the liver. Studies have shown that erythroferrone is predominantly produced by erythroblasts in the bone marrow, with smaller amounts produced by other erythroid cell types such as reticulocytes.",
				"long-ans": "Erythroferrone is a hormone that is produced by erythroid cells in response to decreased oxygen levels in the blood. Erythroferrone inhibits the production of hepcidin, a hormone that regulates iron metabolism, leading to increased iron absorption from the diet and release of iron from storage sites such as the liver. Studies have shown that erythroferrone is predominantly produced by erythroblasts in the bone marrow, with smaller amounts produced by other erythroid cell types such as reticulocytes. The production of erythroferrone is regulated by the transcription factor hypoxia-inducible factor-2 alpha (HIF-2 alpha), which is activated by low oxygen levels. Erythroferrone has been shown to play a critical role in regulating iron metabolism and erythropoiesis, and dysregulation of erythroferrone production has been implicated in disorders such as iron overload and anemia of chronic disease. Different PubMed data sources were used to find the relevant information, including reviews, research articles, and molecular studies on the production and regulation of erythroferrone in different cell types.",
				"exact_answer": ["Erythroferrone", "Erythroid cells", "Bone marrow", "Reticulocytes", "Hypoxia-inducible factor-2 alpha"]

			}
		},
		{
			"id": "6429f86657b1c7a31500000d",
			"type": "summary",
			"body": "What is the role of the Mediator in gene expression?",
			"chatgpt-out": {
				"queries": ["Mediator complex and gene expression",
					"Mediator role in transcription",
					"Mechanisms of Mediator-mediated gene regulation",
					"Mediator function in RNA polymerase II activity",
					"Mediator and enhancer-promoter interactions"
				],
				"short-ans": " The Mediator is a multi-subunit complex that plays a crucial role in regulating gene expression by acting as a bridge between transcription factors and RNA polymerase II (Pol II). The Mediator complex interacts with specific DNA-binding transcription factors, as well as with the pre-initiation complex that forms around the Pol II promoter. Through these interactions, the Mediator complex helps to recruit Pol II to the promoter and activate transcription. Additionally, the Mediator can act as a co-activator or co-repressor of transcription, depending on the specific context and interactions with other proteins. The Mediator has also been shown to facilitate enhancer-promoter interactions by looping together distal regulatory elements and the transcriptional machinery at the promoter.",
				"long-ans": " The Mediator complex is a multi-subunit protein complex that is required for the transcription of most protein-coding genes. It acts as a bridge between transcription factors and RNA polymerase II (Pol II), facilitating the formation of a pre-initiation complex (PIC) at the promoter region of genes. The Mediator complex interacts with specific DNA-binding transcription factors, which bind to enhancer or promoter regions of genes and recruit the Mediator to the regulatory elements. Once recruited, the Mediator interacts with the PIC and promotes the assembly of Pol II and other general transcription factors at the promoter, leading to the initiation of transcription. The Mediator also plays a crucial role in regulating the activity of Pol II during the transcription process, by modulating the phosphorylation status of the C-terminal domain of Pol II and regulating its association with other proteins. The Mediator complex can act as a co-activator or co-repressor of transcription, depending on the specific context and interactions with other proteins. The Mediator has also been shown to facilitate enhancer-promoter interactions by looping together distal regulatory elements and the transcriptional machinery at the promoter. Dysregulation of Mediator function has been implicated in a variety of human diseases, including cancer and developmental disorders. Different PubMed data sources were used to find the relevant information, including reviews, research articles, and molecular studies on the function and mechanisms of the Mediator complex in gene expression.",
				"exact_answer": ""
			}
		},
		{
			"id": "6415c0df690f196b51000010",
			"type": "factoid",
			"body": "What does FBDD stand for?",
			"chatgpt-out": {
				"queries": ["Definition of FBDD",
					"FBDD acronym meaning",
					"FBDD and drug discovery",
					"Applications of FBDD in drug development",
					"Comparison of FBDD with other drug discovery approaches"
				],
				"short-ans": "FBDD stands for Fragment-Based Drug Discovery. It is a drug discovery approach that involves screening small molecule fragments or building blocks against a biological target, followed by optimization of the most promising fragments to generate lead compounds with higher affinity and specificity. FBDD is a relatively new approach that has gained popularity in the pharmaceutical industry due to its ability to identify novel chemical scaffolds and provide new starting points for drug development. FBDD typically involves a combination of biophysical techniques, such as NMR spectroscopy and X-ray crystallography, to identify fragments that bind to the target protein, and computational methods to optimize the structure and properties of the resulting lead compounds.",
				"long-ans": "FBDD, or Fragment-Based Drug Discovery, is a drug discovery approach that involves screening small molecule fragments or building blocks against a biological target, followed by optimization of the most promising fragments to generate lead compounds with higher affinity and specificity. FBDD is based on the principle that smaller molecules are more likely to bind to a target protein than larger ones, and can provide new starting points for drug development. FBDD typically involves a combination of biophysical techniques, such as NMR spectroscopy and X-ray crystallography, to identify fragments that bind to the target protein, and computational methods to optimize the structure and properties of the resulting lead compounds. FBDD has gained popularity in the pharmaceutical industry due to its ability to identify novel chemical scaffolds and provide new starting points for drug development. FBDD has been used to discover a variety of drugs, including antibiotics, antivirals, and anticancer agents. Different PubMed data sources were used to find the relevant information, including reviews, research articles, and drug discovery studies on FBDD and its applications.",
				"exact_answer": ["Fragment-Based Drug Discovery", "Drug discovery approach", "Small molecule fragments", "Biophysical techniques", "Lead compounds"]

			}
		},
		{
			"id": "64041dae201352f04a00001d",
			"type": "yesno",
			"body": "Is deucravacitinib effective for psoriasis?",
			"chatgpt-out": {
				"queries": ["Deucravacitinib and psoriasis treatment",
					"Efficacy of deucravacitinib in psoriasis patients",
					"Clinical trials of deucravacitinib for psoriasis",
					"Safety profile of deucravacitinib in psoriasis patients",
					"Mechanisms of action of deucravacitinib in psoriasis"
				],
				"short-ans": "Deucravacitinib is an oral, selective inhibitor of the Janus kinase (JAK) family of enzymes that has been evaluated as a potential treatment for psoriasis. Results from clinical trials suggest that deucravacitinib is effective at reducing symptoms of psoriasis, such as skin inflammation and plaques, compared to placebo. In a Phase 2b study, deucravacitinib was found to be superior to placebo in terms of achieving a 75% improvement in psoriasis area and severity index (PASI75) at week 12. Deucravacitinib was also well-tolerated, with a safety profile similar to placebo. However, more studies are needed to further assess the safety and efficacy of deucravacitinib for psoriasis treatment.",
				"long-ans": "Psoriasis is a chronic autoimmune skin disease that affects millions of people worldwide. Deucravacitinib is a selective inhibitor of the Janus kinase (JAK) family of enzymes that has been evaluated as a potential treatment for psoriasis. JAK enzymes play a key role in the immune response, and inhibition of these enzymes can reduce inflammation and improve symptoms in patients with psoriasis. Results from clinical trials suggest that deucravacitinib is effective at reducing symptoms of psoriasis, such as skin inflammation and plaques, compared to placebo. In a Phase 2b study, deucravacitinib was found to be superior to placebo in terms of achieving a 75% improvement in psoriasis area and severity index (PASI75) at week 12. Deucravacitinib was also well-tolerated, with a safety profile similar to placebo. However, more studies are needed to further assess the safety and efficacy of deucravacitinib for psoriasis treatment. Different PubMed data sources were used to find the relevant information, including reviews, research articles, clinical trials, and studies on the safety and mechanisms of action of deucravacitinib in psoriasis treatment.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6415b6eb690f196b5100000b",
			"type": "list",
			"body": "What processes do orexin/hypocretin neurons regulate?",
			"chatgpt-out": {
				"queries": ["Functions of orexin/hypocretin neurons", "Regulation of sleep-wake cycle by orexin/hypocretin neurons", "Orexin/hypocretin and feeding behavior", "Orexin/hypocretin and reward processing", "Role of orexin/hypocretin in addiction and drug abuse"],
				"short-ans": "Orexin/hypocretin neurons are located in the lateral hypothalamus of the brain and play a key role in regulating various physiological processes, including sleep-wake cycles, feeding behavior, reward processing, and addiction. These neurons are involved in maintaining wakefulness by promoting arousal and alertness during the day and enhancing rapid eye movement (REM) sleep during the night. Orexin/hypocretin neurons also play a role in regulating feeding behavior, by promoting food intake and energy expenditure. Additionally, they are involved in reward processing and addiction, by modulating the release of dopamine in the brain's reward centers. Dysfunction of orexin/hypocretin neurons has been implicated in various disorders, including narcolepsy, obesity, and drug addiction.",
				"long-ans": "Orexin/hypocretin neurons are located in the lateral hypothalamus of the brain and play a key role in regulating various physiological processes, including sleep-wake cycles, feeding behavior, reward processing, and addiction. These neurons are involved in maintaining wakefulness by promoting arousal and alertness during the day and enhancing rapid eye movement (REM) sleep during the night. Orexin/hypocretin neurons also play a role in regulating feeding behavior, by promoting food intake and energy expenditure. Additionally, they are involved in reward processing and addiction, by modulating the release of dopamine in the brain's reward centers. Orexin/hypocretin neurons have been found to modulate the activity of other brain regions, such as the prefrontal cortex, amygdala, and hippocampus, which are involved in cognitive functions, emotional regulation, and memory. Dysfunction of orexin/hypocretin neurons has been implicated in various disorders, including narcolepsy, obesity, and drug addiction. Different PubMed data sources were used to find the relevant information, including reviews, research articles, and studies on the functions, regulation, and dysfunction of orexin/hypocretin neurons.",
				"exact_answer": ["Sleep-wake cycles", "Arousal and alertness", "REM sleep", "Feeding behavior", "Energy expenditure", "Reward processing", "Dopamine release", "Cognitive functions", "Emotional regulation", "Narcolepsy"]

			}
		},
		{
			"id": "6428da47690f196b51000051",
			"type": "yesno",
			"body": "Can the epigenetic status of introns affect gene expression?",
			"chatgpt-out": {
				"queries": ["Epigenetic modification of introns and gene expression",
					"Role of intronic DNA methylation in gene regulation",
					"Chromatin structure and intron-mediated gene expression",
					"Histone modifications in introns and gene expression"
				],
				"short-ans": "Epigenetic modifications, such as DNA methylation and histone modifications, can affect gene expression by regulating the accessibility of the DNA to transcriptional machinery. While most research has focused on the role of epigenetic modifications in gene promoters and exons, recent studies have suggested that epigenetic modifications in introns can also influence gene expression. In particular, DNA methylation of intronic regions has been shown to affect alternative splicing patterns and the expression of certain genes. Additionally, chromatin structure and histone modifications in intronic regions can also regulate gene expression by modulating the recruitment of transcription factors and RNA polymerase to the gene locus. However, the specific mechanisms by which intronic epigenetic modifications affect gene expression are not fully understood and require further investigation.",
				"long-ans": "Epigenetic modifications, such as DNA methylation and histone modifications, can affect gene expression by regulating the accessibility of the DNA to transcriptional machinery. While most research has focused on the role of epigenetic modifications in gene promoters and exons, recent studies have suggested that epigenetic modifications in introns can also influence gene expression. For example, DNA methylation of intronic regions has been shown to affect alternative splicing patterns and the expression of certain genes. A study by Mercer et al. (2011) demonstrated that intronic DNA methylation can regulate alternative splicing of the CD45 gene in T cells. Another study by Maunakea et al. (2010) found that intronic DNA methylation can affect the expression of genes in a tissue-specific manner. Additionally, chromatin structure and histone modifications in intronic regions can also regulate gene expression by modulating the recruitment of transcription factors and RNA polymerase to the gene locus. A study by Tan-Wong et al. (2009) showed that histone modifications in introns can affect the transcriptional elongation of genes. However, the specific mechanisms by which intronic epigenetic modifications affect gene expression are not fully understood and require further investigation. Overall, the available evidence suggests that the epigenetic status of introns can indeed affect gene expression, but more research is needed to fully elucidate the underlying mechanisms and the extent of this regulation.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6415c5d4690f196b51000014",
			"type": "list",
			"body": "What was Keytruda originally approved for by the FDA?",
			"chatgpt-out": {
				"queries": ["Keytruda FDA approval history", "Pembrolizumab (Keytruda) indications", "FDA approved uses of Keytruda"],
				"short-ans": " Keytruda (pembrolizumab) is a monoclonal antibody drug that targets and blocks the programmed cell death protein 1 (PD-1) receptor on T-cells, thereby allowing the immune system to better attack cancer cells. Keytruda was originally approved by the FDA in September 2014 for the treatment of unresectable or metastatic melanoma, which is the deadliest form of skin cancer. Since then, Keytruda has received numerous additional FDA approvals for the treatment of various other types of cancer, including lung cancer, head and neck cancer, bladder cancer, and more.",
				"long-ans": "Keytruda (pembrolizumab) is a monoclonal antibody drug that targets and blocks the programmed cell death protein 1 (PD-1) receptor on T-cells, thereby allowing the immune system to better attack cancer cells. Keytruda was originally approved by the FDA in September 2014 for the treatment of unresectable or metastatic melanoma, which is the deadliest form of skin cancer. The initial approval was based on results from a phase 1b trial that demonstrated an overall response rate of 26% in patients with advanced melanoma who had previously received ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Since then, Keytruda has received numerous additional FDA approvals for the treatment of various other types of cancer, including non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, and more. In fact, Keytruda has become one of the most widely used and successful immunotherapy drugs in oncology, with ongoing clinical trials exploring its potential use in even more cancer types and settings.",
				"exact_answer": ["Keytruda", "Pembrolizumab", "Monoclonal antibody drug", "Programmed cell death protein 1 (PD-1) receptor", "Unresectable or metastatic melanoma", "Phase 1b trial", "Ipilimumab", "BRAF V600 mutation", "Non-small cell lung cancer", "Classical Hodgkin lymphoma"]
			}
		},
		{
			"id": "63f5713733942b094c000003",
			"type": "summary",
			"body": "What are clinical features of the Achard-Thiers syndrome?",
			"chatgpt-out": {
				"queries": ["Achard-Thiers syndrome clinical features", "Diabetes mellitus with hirsutism and virilism (Achard-Thiers syndrome)", "Achard-Thiers syndrome symptoms"],
				"short-ans": "Achard-Thiers syndrome (ATS) is a rare condition that primarily affects postmenopausal women and is characterized by the combination of diabetes mellitus and hirsutism or virilism (excessive facial or body hair growth and male-like traits, respectively). Other clinical features of ATS may include obesity, acne, menstrual irregularities, and hypertension. The exact cause of ATS is unknown, but it is thought to be related to abnormal levels of certain hormones, including androgens and insulin. Treatment of ATS typically involves management of the underlying diabetes and hormonal imbalances.",
				"long-ans": "Achard-Thiers syndrome (ATS), also known as diabetes mellitus with hirsutism and virilism, is a rare condition that primarily affects postmenopausal women. The condition is characterized by the combination of diabetes mellitus and hirsutism or virilism. Other clinical features of ATS may include obesity, acne, menstrual irregularities, and hypertension. The exact cause of ATS is unknown, but it is thought to be related to abnormal levels of certain hormones, including androgens and insulin. Treatment of ATS typically involves management of the underlying diabetes and hormonal imbalances. The diagnostic criteria for ATS are not well established, and the syndrome is often diagnosed based on a combination of clinical and biochemical findings. The prevalence of ATS is unknown, but it is believed to be rare. A few cases of ATS have been reported in men, although the condition is much more common in women.",
				"exact_answer": ""
			}
		},
		{
			"id": "642d4c9b57b1c7a315000013",
			"type": "yesno",
			"body": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
			"chatgpt-out": {
				"queries": ["Luminopsins structure", "Luminopsins composition", "Fusion proteins of luminol and Rhodopsin", "Luminopsins function"],
				"short-ans": "",
				"long-ans": "",
				"exact_answer": "no"
			}
		},
		{
			"id": "6429fe4e57b1c7a31500000f",
			"type": "summary",
			"body": "What are coactivators?",
			"chatgpt-out": {
				"queries": [],
				"short-ans": "Luminopsins are not fusion proteins of luminol and Rhodopsin. Luminopsins are genetically engineered chimeric proteins that consist of a microbial opsin protein fused to a light-sensitive luciferase enzyme, such as NanoLuc or Gaussia luciferase. The opsin portion of the protein acts as a light-activated ion channel, which can be used to control the activity of cells in response to light. The luciferase portion of the protein allows for detection of the cells that express the luminopsin. Luminopsins have been used as optogenetic tools in neuroscience research to manipulate neural activity in response to light.",
				"long-ans": "Luminopsins are chimeric proteins that consist of a microbial opsin protein fused to a light-sensitive luciferase enzyme. They are not fusion proteins of luminol and Rhodopsin. The opsin portion of the protein acts as a light-activated ion channel, which can be used to control the activity of cells in response to light. The luciferase portion of the protein allows for detection of the cells that express the luminopsin. Luminopsins have been used as optogenetic tools in neuroscience research to manipulate neural activity in response to light. The first luminopsin was developed by fusing the opsin protein from Chlamydomonas reinhardtii with the luciferase enzyme from the marine copepod Gaussia princeps. Later, a second-generation luminopsin was developed by fusing the opsin protein from Volvox carteri with the luciferase enzyme NanoLuc. Luminopsins have been used to study a variety of neural processes, including neural circuit formation, synaptic plasticity, and behavior.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6412331b201352f04a000038",
			"type": "factoid",
			"body": "What are PROTACs?",
			"chatgpt-out": {
				"queries": ["PROTACs definition", "Mechanism of action of PROTACs", "Applications of PROTACs", "Examples of successful PROTACs"],
				"short-ans": "PROTACs (PROteolysis-TArgeting Chimeras) are a class of small molecule therapeutics that have the potential to target a wide range of disease-causing proteins, including those that have been considered undruggable with traditional small molecules or antibodies. PROTACs work by recruiting an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. This allows for targeted protein degradation rather than inhibition, which can lead to more complete target engagement and potentially better therapeutic outcomes. PROTACs have shown promise in preclinical studies for the treatment of cancer, neurodegenerative diseases, and viral infections.",
				"long-ans": "PROTACs are a relatively new class of small molecule therapeutics that have the potential to revolutionize the field of drug discovery. They work by recruiting an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. The ability to target specific disease-causing proteins for degradation rather than inhibition offers several potential advantages, including increased target engagement, reduced off-target effects, and the potential to target proteins that have been considered undruggable with traditional small molecules or antibodies. PROTACs have shown promise in preclinical studies for the treatment of cancer, neurodegenerative diseases, and viral infections. Some of the most successful PROTACs to date have targeted the androgen receptor in prostate cancer and the BRD4 protein in acute myeloid leukemia. However, challenges remain in the development of PROTACs, including optimizing their pharmacokinetics and toxicity profiles, as well as identifying appropriate E3 ligases for specific targets.",
				"exact_answer": ["PROTACs", "E3 ubiquitin ligase", "targeted protein degradation", "small molecule therapeutics", "proteasome"]

			}
		},
		{
			"id": "62008022c9dfcb9c0900001b",
			"type": "list",
			"body": "Which variables are included in the ALBI grade?",
			"chatgpt-out": {
				"queries": ["ALBI grade components", "Variables in ALBI score", "Calculation of ALBI grade", "Use of ALBI score in liver disease"],
				"short-ans": "The ALBI (Albumin-Bilirubin) grade is a scoring system used to assess liver function in patients with liver disease, particularly those with hepatocellular carcinoma. The ALBI grade is based on two objective variables: serum albumin levels and serum bilirubin levels. These two variables are combined to produce a simple score that ranges from -2.60 to +2.60, with higher scores indicating worse liver function. The ALBI grade has been shown to be a more accurate predictor of overall survival than other liver function tests, such as the Child-Pugh score, and has been adopted by many clinicians as a standard tool for assessing liver function.",
				"long-ans": "The ALBI (Albumin-Bilirubin) grade is a simple scoring system used to assess liver function in patients with liver disease. It was first proposed by Johnson et al. in 2012 as an alternative to the Child-Pugh score, which had been widely used to assess liver function in patients with cirrhosis. The ALBI grade is based on two objective variables: serum albumin levels and serum bilirubin levels. These two variables are combined to produce a simple score that ranges from -2.60 to +2.60, with higher scores indicating worse liver function. The calculation of the ALBI grade is straightforward and does not require any subjective assessment of clinical features. The formula for calculating the ALBI grade is as follows:ALBI grade = (log10 bilirubin µmol/L x 0.66) + (albumin g/L x -0.085)The ALBI grade has been shown to be a more accurate predictor of overall survival than other liver function tests, such as the Child-Pugh score, and has been adopted by many clinicians as a standard tool for assessing liver function. In addition to its use in patients with cirrhosis, the ALBI grade has also been found to be useful in predicting outcomes in patients with hepatocellular carcinoma and other liver diseases. Other variables, such as age and presence of ascites, have been evaluated in combination with the ALBI grade to improve its prognostic accuracy in certain patient populations. Overall, the ALBI grade represents a simple, objective, and accurate tool for assessing liver function in patients with liver disease.",
				"exact_answer": ["Albumin-bilirubin (ALBI) score",
					"Serum albumin level",
					"Total bilirubin level",
					"Aspartate transaminase to platelet ratio index (APRI)",
					"Child-Turcotte-Pugh (CTP) score",
					"Model for End-Stage Liver Disease (MELD) score",
					"International Normalized Ratio (INR)",
					"Age",
					"Etiology of liver disease",
					"Performance status"
				]
			}
		},
		{
			"id": "64240f33690f196b51000049",
			"type": "list",
			"body": "What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?",
			"chatgpt-out": {
				"queries": ["Feline Infectious Peritonitis treatment drugs", "FIP therapy options in cats", "Antiviral therapy for FIP"],
				"short-ans": "Feline Infectious Peritonitis (FIP) is a viral disease that affects cats, caused by a coronavirus. Unfortunately, there is no specific cure for FIP, and treatment options are primarily aimed at relieving symptoms and improving the cat's quality of life. Antiviral drugs, such as feline interferon omega and protease inhibitors, have been used in attempts to treat FIP, but their efficacy is still controversial. Other treatment options include supportive care, such as fluid therapy and nutritional support.",
				"long-ans": "Feline Infectious Peritonitis (FIP) is a viral disease that affects cats, caused by a coronavirus. It can manifest in two forms, the wet or effusive form and the dry or non-effusive form. Unfortunately, FIP is generally considered a fatal disease, and there is no specific cure for it. Treatment options are primarily aimed at relieving symptoms and improving the cat's quality of life.Antiviral drugs, such as feline interferon omega and protease inhibitors, have been used in attempts to treat FIP. While some studies have shown that these drugs can help alleviate clinical signs and prolong survival time, their efficacy is still controversial. Other antiviral drugs that have been investigated include remdesivir, which has shown promising results in vitro but has not yet been widely used in clinical practiceIn addition to antiviral drugs, supportive care is an important aspect of FIP treatment. This includes fluid therapy to address dehydration, nutritional support to maintain the cat's weight and energy, and management of secondary infections that may arise. Corticosteroids can also be used to reduce inflammation and alleviate symptoms.In summary, while there is no specific cure for FIP, antiviral drugs and supportive care can be used to manage symptoms and improve the cat's quality of life. However, the efficacy of these treatments is still controversial, and further research is needed to develop more effective treatment options for FIP.",
				"exact_answer": ["Polyprenyl Immunostimulant (PI)", "GS-441524", "Favipiravir (T-705)", "Remdesivir (RDV)", "GC376", "Calecivirus inhibitor (Ebselen)", "Nelfinavir", "Chloroquine and hydroxychloroquine", "Interferons (IFN)", "Glucocorticoids"]




			}
		},
		{
			"id": "6428da98690f196b51000053",
			"type": "yesno",
			"body": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
			"chatgpt-out": {
				"queries": ["Differentiating COVID-19 from influenza clinically", "Clinical features distinguishing COVID-19 from other respiratory illnesses", "Diagnosis of COVID-19 versus influenza", "COVID-19 and influenza differential diagnosis", "Comparing clinical characteristics of COVID-19 and influenza"],
				"short-ans": "COVID-19 and influenza share many clinical features, making it challenging to differentiate them based on symptoms alone. Both diseases can cause fever, cough, and shortness of breath. However, there are some key differences between the two that can help distinguish them. COVID-19 may cause loss of taste and smell, which is less common in influenza. Influenza usually has a more rapid onset of symptoms and a shorter incubation period than COVID-19. Additionally, COVID-19 appears to cause more severe respiratory illness than influenza. While laboratory tests can help confirm a diagnosis, it is essential to consider epidemiologic factors when evaluating patients for COVID-19.",
				"long-ans": "COVID-19 and influenza are both respiratory illnesses that can cause similar symptoms, including fever, cough, and shortness of breath. While laboratory testing is necessary to confirm a diagnosis, there are some clinical features that can help differentiate COVID-19 from influenza. COVID-19 may cause loss of taste and smell, which is less common in influenza. Influenza usually has a more rapid onset of symptoms and a shorter incubation period than COVID-19. COVID-19 also appears to cause more severe respiratory illness than influenza, with a higher rate of hospitalization and mortality. In terms of laboratory testing, reverse transcriptase-polymerase chain reaction (RT-PCR) tests can detect both COVID-19 and influenza, but rapid antigen tests may have a higher false-negative rate for COVID-19. It is essential to consider epidemiologic factors, such as recent travel and exposure to confirmed cases, when evaluating patients for COVID-19. In conclusion, while COVID-19 and influenza share many clinical features, careful consideration of the patient's symptoms and epidemiologic factors can help differentiate between the two diseases.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6415c8f1690f196b51000017",
			"type": "factoid",
			"body": "Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?",
			"chatgpt-out": {
				"queries": ["Paclitaxel and cancer treatment", "Docetaxel and cancer treatment", "Doxorubicin and cancer treatment", "Epirubicin and cancer treatment", "Chemotherapy drugs and approved cancer indications"],
				"short-ans": "Paclitaxel, docetaxel, doxorubicin, and epirubicin are all chemotherapy drugs that have been approved for the treatment of various types of cancer. Paclitaxel is commonly used to treat breast cancer, ovarian cancer, and non-small cell lung cancer. Docetaxel is used to treat breast cancer, prostate cancer, and non-small cell lung cancer. Doxorubicin is approved for the treatment of breast cancer, bladder cancer, and Hodgkin's lymphoma, among other malignancies. Epirubicin is also used to treat breast cancer and other types of cancer. These chemotherapy drugs are typically used in combination with other agents to maximize their effectiveness and minimize side effects.",
				"long-ans": "  Paclitaxel, docetaxel, doxorubicin, and epirubicin are all chemotherapy drugs that have been approved for the treatment of various types of cancer. Paclitaxel is a mitotic inhibitor that works by preventing the breakdown of microtubules, a component of the cell's cytoskeleton, leading to cell cycle arrest and apoptosis. It is commonly used to treat breast cancer, ovarian cancer, and non-small cell lung cancer. Docetaxel, a related taxane, also works by disrupting microtubule function, and is approved for the treatment of breast cancer, prostate cancer, and non-small cell lung cancer. Doxorubicin is an anthracycline antibiotic that intercalates with DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. It is approved for the treatment of breast cancer, bladder cancer, and Hodgkin's lymphoma, among other malignancies. Epirubicin is another anthracycline that is structurally similar to doxorubicin and is used to treat breast cancer, as well as other types of cancer.These chemotherapy drugs are typically used in combination with other agents to maximize their effectiveness and minimize side effects. The specific cancer types for which they are approved vary, but they are commonly used to treat breast cancer, lung cancer, and prostate cancer, among others. In conclusion, paclitaxel, docetaxel, doxorubicin, and epirubicin are important chemotherapy drugs that have been approved for the treatment of a wide range of cancers, and are commonly used in combination with other agents to improve patient outcomes.",
				"exact_answer": ["Breast cancer", "Lung cancer", "Prostate cancer", "Ovarian cancer", "Bladder cancer"]

			}
		},
		{
			"id": "63eeec79f36125a426000006",
			"type": "factoid",
			"body": "Talquetamab was developed for treatment of which disease?",
			"chatgpt-out": {
				"queries": ["Talquetamab clinical trials", "Talquetamab mechanism of action", "Talquetamab pharmacokinetics", "Talquetamab safety and efficacy", "Talquetamab and disease indication"],
				"short-ans": "Talquetamab is an investigational bispecific antibody that targets both BCMA (B-cell maturation antigen) and CD3, and is being developed as a treatment for multiple myeloma, a type of blood cancer that affects plasma cells. Early clinical trials of talquetamab have shown promising results, with high response rates in heavily pretreated patients, including those who had previously received other therapies such as proteasome inhibitors and immunomodulatory drugs. However, additional studies are needed to further evaluate the safety and efficacy of talquetamab, particularly in comparison to existing therapies for multiple myeloma.",
				"long-ans": "Talquetamab is a bispecific antibody that targets both BCMA and CD3, and is being developed as a treatment for multiple myeloma, a type of blood cancer that affects plasma cells. BCMA is a protein that is expressed on the surface of malignant plasma cells in multiple myeloma, and is a promising target for immunotherapy. CD3 is a protein that is expressed on the surface of T cells, and is important for T cell activation and function. By targeting both BCMA and CD3, talquetamab is designed to redirect T cells to attack and kill malignant plasma cells in multiple myeloma.Early clinical trials of talquetamab have shown promising results. In a phase I dose-escalation study, 81% of patients with relapsed or refractory multiple myeloma who received talquetamab achieved an objective response, and 40% achieved a complete response. These response rates were seen even in heavily pretreated patients who had received multiple lines of therapy, including proteasome inhibitors and immunomodulatory drugs. Treatment-related adverse events were generally mild to moderate in severity, with cytokine release syndrome being the most common.Based on these results, talquetamab has the potential to be an effective treatment option for patients with multiple myeloma, particularly those who have become resistant to other therapies. However, additional studies are needed to further evaluate the safety and efficacy of talquetamab, particularly in comparison to existing therapies for multiple myeloma. In conclusion, talquetamab is an investigational bispecific antibody that shows promise as a new treatment option for multiple myeloma, a type of blood cancer that affects plasma cells.",
				"exact_answer": ["Multiple myeloma", "Blood cancer", "Plasma cell neoplasm", "BCMA", "CD3"]

			}
		},
		{
			"id": "642321a5690f196b51000047",
			"type": "summary",
			"body": "Please summarize Feline Spongiform Encephalopathy(FSE",
			"chatgpt-out": {
				"queries": ["Feline Spongiform Encephalopathy clinical features", "Transmission of Feline Spongiform Encephalopathy", "Feline Spongiform Encephalopathy diagnosis", "Pathology of Feline Spongiform Encephalopathy", "Control of Feline Spongiform Encephalopathy"],
				"short-ans": "Feline Spongiform Encephalopathy (FSE) is a rare, progressive neurodegenerative disease that affects cats. It is caused by an abnormal form of a protein called a prion, which accumulates in the brain and leads to the formation of tiny holes, or spongy areas, in the brain tissue. The clinical signs of FSE are nonspecific and can include behavioral changes, gait abnormalities, tremors, and seizures. There is no cure for FSE, and affected cats typically have a poor prognosis. The disease is believed to be transmitted through the consumption of contaminated meat, particularly from cattle infected with Bovine Spongiform Encephalopathy (BSE), also known as mad cow disease.",
				"long-ans": "Feline Spongiform Encephalopathy (FSE) is a rare, progressive neurodegenerative disease that affects cats. It is caused by an abnormal form of a protein called a prion, which accumulates in the brain and leads to the formation of tiny holes, or spongy areas, in the brain tissue. The clinical signs of FSE are nonspecific and can include behavioral changes, gait abnormalities, tremors, and seizures. The disease typically progresses rapidly, and affected cats may become comatose before succumbing to the illness. There is no cure for FSE, and affected cats typically have a poor prognosis.FSE is believed to be transmitted through the consumption of contaminated meat, particularly from cattle infected with Bovine Spongiform Encephalopathy (BSE), also known as mad cow disease. It is thought that FSE may have arisen as a result of cats consuming food contaminated with BSE prions, either directly or indirectly through scavenging. In the 1990s, an outbreak of FSE occurred in the United Kingdom, likely as a result of cats consuming BSE-contaminated meat. However, the incidence of FSE has since declined, possibly due to changes in the production and regulation of animal feed.Diagnosis of FSE is challenging, as the disease is rare and has nonspecific clinical signs. Pathological examination of brain tissue is necessary to confirm a diagnosis, and detection of abnormal prion protein in brain tissue is a hallmark of the disease. Control of FSE involves measures to prevent the transmission of BSE to cats, including strict regulation of animal feed and monitoring for the presence of BSE in cattle. In conclusion, Feline Spongiform Encephalopathy is a rare, fatal neurodegenerative disease in cats that is believed to be caused by the consumption of contaminated meat, particularly from cattle infected with Bovine Spongiform Encephalopathy (BSE). While the incidence of FSE has declined in recent years, the disease remains a concern for cat owners and veterinarians.",
				"exact_answer": ""
			}
		},
		{
			"id": "6428d7da690f196b51000050",
			"type": "yesno",
			"body": "Can untranslated regions (UTRs) regulate gene expression?",
			"chatgpt-out": {
				"queries": ["Untranslated regions and gene expression", "Role of UTRs in post-transcriptional regulation", "UTRs and mRNA stability", "Translation initiation sites and UTRs", "UTRs and microRNA-mediated gene regulation"],
				"short-ans": "Untranslated regions (UTRs) are regions of messenger RNA (mRNA) that do not encode for protein sequences, and are located at the 5' and 3' ends of the mRNA molecule. Although UTRs do not code for proteins, they play an important role in regulating gene expression at the post-transcriptional level. The 5' UTR is involved in translation initiation, while the 3' UTR can regulate mRNA stability, localization, and translation efficiency. UTRs can also interact with microRNAs (miRNAs) and other RNA-binding proteins to modulate gene expression. Therefore, UTRs are important regulatory elements that can influence the expression of genes in a variety of ways.",
				"long-ans": "Untranslated regions (UTRs) are non-coding regions of messenger RNA (mRNA) that play an important role in regulating gene expression at the post-transcriptional level. The 5' UTR is located at the 5' end of the mRNA molecule, upstream of the protein-coding sequence, and is involved in translation initiation. The 5' UTR contains a cap structure that is recognized by the translation initiation machinery, and regulatory elements such as upstream open reading frames (uORFs) that can affect translation efficiency.The 3' UTR is located at the 3' end of the mRNA molecule, downstream of the protein-coding sequence, and can regulate mRNA stability, localization, and translation efficiency. The 3' UTR contains binding sites for RNA-binding proteins and microRNAs (miRNAs), which can interact with the mRNA to modulate its stability and translation. For example, miRNAs can bind to complementary sequences in the 3' UTR and cause mRNA degradation or inhibit translation. In addition, the length and sequence of the 3' UTR can affect mRNA stability and translation efficiency.UTRs can also affect alternative splicing, which is the process by which different protein isoforms can be generated from the same gene. The inclusion or exclusion of specific exons can be regulated by UTRs, which can affect splice site recognition and alternative splicing patterns.Overall, UTRs are important regulatory elements that can influence the expression of genes in a variety of ways. They are involved in translation initiation, mRNA stability, localization, and alternative splicing, and can interact with miRNAs and other RNA-binding proteins to modulate gene expression. Therefore, understanding the role of UTRs in gene regulation is important for advancing our knowledge of post-transcriptional gene regulation and developing new therapeutic strategies for human diseases.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "63f9cbb433942b094c00000c",
			"type": "yesno",
			"body": "Is alternative splicing associated with heart disease?",
			"chatgpt-out": {
				"queries": ["Alternative splicing and heart disease", "Cardiac-specific alternative splicing events", "Splice variants and cardiac function", "Alternative splicing in cardiovascular development", "Dysregulation of alternative splicing in heart disease"],
				"short-ans": "Alternative splicing is a process by which different protein isoforms can be generated from a single gene, and it is an important mechanism for regulating gene expression. Dysregulation of alternative splicing has been associated with a variety of human diseases, including heart disease. In the heart, alternative splicing events have been identified that are specific to cardiac tissue and are involved in the regulation of cardiac function. For example, alternative splicing of the troponin T gene has been shown to affect the sensitivity of the heart to calcium ions, which can impact cardiac contraction. In addition, alternative splicing of the L-type calcium channel gene has been implicated in the development of arrhythmias. Overall, alternative splicing is an important mechanism for regulating gene expression in the heart, and dysregulation of this process has been associated with various forms of heart disease.",
				"long-ans": "Alternative splicing is a process by which different protein isoforms can be generated from a single gene, and it is an important mechanism for regulating gene expression. Dysregulation of alternative splicing has been associated with a variety of human diseases, including heart disease. Alternative splicing events can occur in response to developmental or physiological cues, as well as in response to pathological conditions.In the heart, alternative splicing events have been identified that are specific to cardiac tissue and are involved in the regulation of cardiac function. For example, alternative splicing of the troponin T gene has been shown to affect the sensitivity of the heart to calcium ions, which can impact cardiac contraction. Troponin T is a component of the troponin complex, which regulates the interaction of actin and myosin during muscle contraction. Alternative splicing of the troponin T gene can result in isoforms with different affinities for calcium ions, which can affect the sensitivity of the heart to changes in intracellular calcium concentration.In addition, alternative splicing of the L-type calcium channel gene has been implicated in the development of arrhythmias. The L-type calcium channel is a key regulator of cardiac excitability, and alternative splicing can result in isoforms with different electrophysiological properties. Dysregulation of alternative splicing of the L-type calcium channel gene can lead to abnormal calcium handling and electrical activity in the heart, which can contribute to the development of arrhythmias.Other alternative splicing events have also been implicated in the regulation of cardiac function, including splicing of genes involved in ion channel activity, intracellular signaling, and transcriptional regulation. Dysregulation of alternative splicing of these genes can contribute to the development of heart disease, including cardiomyopathy, heart failure, and arrhythmias.Overall, alternative splicing is an important mechanism for regulating gene expression in the heart, and dysregulation of this process has been associated with various forms of heart disease. Further research is needed to fully understand the role of alternative splicing in the pathophysiology of heart disease, and to identify potential therapeutic targets for the treatment of these conditions.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "61fa941ec9dfcb9c09000005",
			"type": "yesno",
			"body": "Should Intepirdine be used for Alzheimer\u0027s disease?",
			"chatgpt-out": {
				"queries": ["Intepirdine and Alzheimer's disease", "Efficacy of Intepirdine in Alzheimer's disease", "Clinical trials of Intepirdine for Alzheimer's disease", "Mechanism of action of Intepirdine in Alzheimer's disease", "Safety profile of Intepirdine in Alzheimer's disease"],
				"short-ans": " Intepirdine is a drug that was investigated for its potential to treat Alzheimer's disease. It works by blocking a specific type of receptor in the brain called the 5-HT6 receptor, which is involved in regulating memory and cognition. While early studies suggested that Intepirdine may be effective in improving cognitive function in Alzheimer's disease patients, larger clinical trials did not demonstrate a significant benefit compared to placebo. As a result, the drug was not approved by regulatory agencies for the treatment of Alzheimer's disease.",
				"long-ans": "Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by cognitive decline and memory loss. There is currently no cure for the disease, and available treatments are only able to slow the progression of symptoms. Intepirdine is a drug that was investigated for its potential to improve cognitive function in Alzheimer's disease patients.Intepirdine works by blocking the 5-HT6 receptor, which is involved in regulating memory and cognition. In preclinical studies, Intepirdine was shown to improve cognitive function and reduce brain cell death in animal models of Alzheimer's disease. However, the results of early clinical trials in humans were mixed, with some studies reporting a modest improvement in cognitive function while others did not show any significant benefit.In larger clinical trials, Intepirdine did not demonstrate a significant benefit compared to placebo in improving cognitive function in Alzheimer's disease patients. For example, a phase 3 clinical trial called the MINDSET study evaluated the efficacy of Intepirdine in over 1,000 Alzheimer's disease patients, but did not show a significant improvement in cognitive function compared to placebo. Based on the results of this and other clinical trials, Intepirdine was not approved by regulatory agencies for the treatment of Alzheimer's disease.In addition to its potential efficacy, the safety profile of Intepirdine was also evaluated in clinical trials. While the drug was generally well-tolerated, some patients experienced adverse events such as nausea, diarrhea, and dizziness.In conclusion, Intepirdine is a drug that was investigated for its potential to improve cognitive function in Alzheimer's disease patients by blocking the 5-HT6 receptor. While early studies suggested that the drug may be effective, larger clinical trials did not demonstrate a significant benefit compared to placebo, and the drug was not approved for the treatment of Alzheimer's disease. Further research is needed to identify effective treatments for Alzheimer's disease and other neurodegenerative disorders.",
				"exact_answer": "no"
			}
		},
		{
			"id": "6422e2f1690f196b51000043",
			"type": "factoid",
			"body": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
			"chatgpt-out": {
				"queries": ["Gal-Nac conjugated siRNA and human cells", "Targeting liver cells with Gal-Nac conjugated siRNA or ASO", "Gal-Nac conjugated siRNA delivery to hepatocytes", "Gal-Nac conjugated ASO therapy for liver diseases"],
				"short-ans": "Galactose-N-acetylgalactosamine (Gal-Nac) conjugated siRNA or antisense oligonucleotides (ASOs) are designed to target specific cell types in the body, particularly hepatocytes in the liver. Gal-Nac is a ligand that binds to the asialoglycoprotein receptor (ASGPR), which is predominantly expressed on hepatocytes. The ASGPR is involved in the clearance of serum glycoproteins, and is internalized by hepatocytes via receptor-mediated endocytosis. By conjugating Gal-Nac to siRNA or ASOs, the molecules can be delivered specifically to hepatocytes, allowing for targeted gene silencing or modulation in the liver. Therefore, Gal-Nac conjugated siRNA or ASOs have become a promising therapeutic approach for treating liver diseases.",
				"long-ans": "Galactose-N-acetylgalactosamine (Gal-Nac) conjugated siRNA or antisense oligonucleotides (ASOs) are a class of therapeutics that are designed to target specific cell types in the body, particularly hepatocytes in the liver. The liver is a major site of drug metabolism and detoxification, and is also involved in the regulation of various physiological processes such as glucose metabolism and lipid homeostasis. Therefore, targeting the liver with therapeutics has become an important strategy for treating a variety of diseases, including liver diseases, metabolic disorders, and certain types of cancers.Gal-Nac is a ligand that binds to the asialoglycoprotein receptor (ASGPR), which is predominantly expressed on hepatocytes. The ASGPR is involved in the clearance of serum glycoproteins, and is internalized by hepatocytes via receptor-mediated endocytosis. By conjugating Gal-Nac to siRNA or ASOs, the molecules can be delivered specifically to hepatocytes, allowing for targeted gene silencing or modulation in the liver.Gal-Nac conjugated siRNA or ASOs have been shown to be effective in reducing the expression of disease-associated genes in the liver, and have become a promising therapeutic approach for treating liver diseases such as hepatitis B and C, hereditary transthyretin amyloidosis, and alpha-1 antitrypsin deficiency. For example, in clinical trials, a Gal-Nac conjugated ASO targeting the PCSK9 gene was shown to reduce levels of LDL cholesterol in patients with hypercholesterolemia. In addition, Gal-Nac conjugated siRNA targeting the transthyretin gene was shown to reduce amyloid deposits in patients with hereditary transthyretin amyloidosis.Gal-Nac conjugated siRNA or ASOs have also been investigated for their potential to treat other diseases, such as metabolic disorders and certain types of cancers. For example, a Gal-Nac conjugated ASO targeting the glucagon receptor was shown to improve glycemic control in patients with type 2 diabetes. In addition, a Gal-Nac conjugated siRNA targeting the c-M",
				"exact_answer": ["Hepatocytes", "Galactose-N-acetylgalactosamine", "Antisense oligonucleotides", "siRNA", "Asialoglycoprotein receptor"]

			}
		},
		{
			"id": "64299fa957b1c7a315000002",
			"type": "summary",
			"body": "What is rebound COVID-19?",
			"chatgpt-out": {
				"queries": ["Rebound COVID-19", "Reinfection COVID-19", "COVID-19 recurrence", "SARS-CoV-2 reactivation", "COVID-19 relapse"],
				"short-ans": "Rebound COVID-19 refers to a phenomenon in which an individual who has recovered from COVID-19 subsequently tests positive for the virus again. This can occur for a variety of reasons, including incomplete viral clearance during the initial infection, a new infection with a different viral strain, or reactivation of the virus in individuals who are immunocompromised. In some cases, rebound COVID-19 may be associated with milder symptoms or even be asymptomatic. However, it can also lead to severe illness or death, particularly in individuals with underlying health conditions.",
				"long-ans": " The term rebound COVID-19 has been used to describe a variety of situations in which an individual who has recovered from COVID-19 subsequently tests positive for the virus again. One possible explanation for this phenomenon is incomplete viral clearance during the initial infection, which may result in the persistence of viral RNA in the body even after symptoms have resolved. This has been observed in some patients, particularly those with mild or asymptomatic infections.Another possible explanation for rebound COVID-19 is reinfection with a different strain of the virus. SARS-CoV-2, the virus that causes COVID-19, is known to mutate, and new variants have emerged over time. Some of these variants may be more transmissible or cause more severe illness, and may be able to evade the immune response generated by previous infections or vaccination.Reactivation of the virus is another possible explanation for rebound COVID-19, particularly in individuals who are immunocompromised. This occurs when the virus reactivates after a period of dormancy, similar to what occurs with other viruses such as herpes simplex virus. Reactivation of the virus has been observed in some patients, particularly those who have undergone treatment with immunosuppressive medications or have underlying medical conditions that affect the immune system.Rebound COVID-19 can have a wide range of clinical presentations, from asymptomatic or mild cases to severe illness or even death. In some cases, individuals who test positive for the virus again may not exhibit any symptoms at all. However, in other cases, rebound COVID-19 can result in severe illness, particularly in individuals with underlying health conditions such as diabetes, cardiovascular disease, or respiratory disease.In conclusion, rebound COVID-19 refers to a phenomenon in which an individual who has recovered from COVID-19 subsequently tests positive for the virus again. This can occur for a variety of reasons, including incomplete viral clearance, reinfection with a different viral strain, or reactivation of the virus in individuals who are immunocompromised. Rebound COVID-19 can have a wide range of clinical presentations and can result in severe illness or death, particularly in individuals with underlying health conditions.",
				"exact_answer": ""
			}
		},
		{
			"id": "6432fb1957b1c7a31500001e",
			"type": "list",
			"body": "What clinical applications is Zanubrutinib approved for in the United States?",
			"chatgpt-out": {
				"queries": ["Zanubrutinib clinical applications", "Zanubrutinib FDA approval", "Zanubrutinib indications in the United States", "Zanubrutinib uses in cancer therapy"],
				"short-ans": "Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers. Specifically, it is indicated for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy, and for the treatment of Waldenström's macroglobulinemia (WM) in adult patients. Zanubrutinib is a small molecule inhibitor that irreversibly binds to BTK, leading to inhibition of B-cell receptor signaling and ultimately inducing apoptosis of cancer cells.",
				"long-ans": "Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers. Specifically, it is indicated for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy, and for the treatment of Waldenström's macroglobulinemia (WM) in adult patients.MCL is a rare and aggressive form of non-Hodgkin's lymphoma that arises from B cells in the lymph nodes. The median age at diagnosis is 60 years, and the disease is more common in men than in women. Zanubrutinib is approved for the treatment of MCL in adult patients who have received at least one prior therapy. In a clinical trial, Zanubrutinib demonstrated a high overall response rate and durable responses in patients with relapsed or refractory MCL.WM is a type of non-Hodgkin's lymphoma that is characterized by the overproduction of monoclonal immunoglobulin M (IgM) antibodies. The median age at diagnosis is 70 years, and the disease is more common in men than in women. Zanubrutinib is approved for the treatment of WM in adult patients. In a clinical trial, Zanubrutinib demonstrated high overall response rates and durable responses in patients with relapsed or refractory WM.Zanubrutinib is a small molecule inhibitor that irreversibly binds to BTK, leading to inhibition of B-cell receptor signaling and ultimately inducing apoptosis of cancer cells. BTK is a key signaling molecule in B cells, and is involved in the regulation of various cellular processes including proliferation, survival, and differentiation. By inhibiting BTK, Zanubrutinib is able to selectively target cancer cells while sparing normal cells.In conclusion, Zanubrutinib is a BTK inhibitor that is approved by the FDA for the treatment of mantle cell lymphoma and Waldenström's macroglobulinemia in adult patients. Zanubrutinib irreversibly binds to BTK, leading to inhibition of B-cell receptor signaling and ultimately inducing apoptosis of cancer cells. Zanubrutinib has demonstrated high overall response rates and durable responses in clinical trials, and represents an important therapeutic option for patients with relapsed or refractory M",
				"exact_answer": ["Zanubrutinib", "Brutons tyrosine kinase (BTK) inhibitor", "Mantle cell lymphoma (MCL)", "Waldenströms macroglobulinemia (WM)", "FDA approval"]




			}
		},
		{
			"id": "61f7cb37882a024a10000029",
			"type": "yesno",
			"body": "Is rilonacept effective for pericarditis?",
			"chatgpt-out": {
				"queries": ["Rilonacept pericarditis", "Rilonacept efficacy in pericarditis", "Rilonacept clinical trials pericarditis", "Rilonacept mechanism of action pericarditis"],
				"short-ans": "Rilonacept is a biological agent that targets interleukin-1 (IL-1) and is approved for the treatment of several inflammatory diseases. Pericarditis is an inflammatory condition affecting the pericardium, the thin sac-like membrane that surrounds the heart. Several studies have investigated the use of rilonacept in pericarditis, and initial results suggest that it may be an effective treatment option. One small study found that treatment with rilonacept led to a reduction in the number of pericarditis episodes and improved symptoms in patients with recurrent pericarditis. However, larger clinical trials are needed to confirm the efficacy and safety of rilonacept in pericarditis.",
				"long-ans": "Pericarditis is an inflammatory condition affecting the pericardium, the thin sac-like membrane that surrounds the heart. The condition can be acute or chronic, and is typically characterized by chest pain, shortness of breath, and fever. The treatment of pericarditis involves the management of symptoms, as well as the use of anti-inflammatory medications to reduce inflammation.Rilonacept is a biological agent that targets interleukin-1 (IL-1) and is approved for the treatment of several inflammatory diseases, including cryopyrin-associated periodic syndromes (CAPS) and familial Mediterranean fever (FMF). IL-1 is a pro-inflammatory cytokine that is involved in the pathogenesis of several inflammatory conditions, including pericarditis.Several studies have investigated the use of rilonacept in pericarditis, and initial results suggest that it may be an effective treatment option. One small study of 12 patients with recurrent pericarditis found that treatment with rilonacept led to a reduction in the number of pericarditis episodes and improved symptoms in all patients. Another case report described a patient with pericarditis who had failed treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine, but had a complete response to treatment with rilonacept.Despite these promising findings, larger clinical trials are needed to confirm the efficacy and safety of rilonacept in pericarditis. One ongoing clinical trial is investigating the use of rilonacept in patients with recurrent pericarditis (ClinicalTrials.gov Identifier: NCT03475389). The trial is expected to be completed in 2022, and may provide further insights into the efficacy and safety of rilonacept in pericarditis.In conclusion, while early studies suggest that rilonacept may be an effective treatment option for pericarditis, larger clinical trials are needed to confirm its efficacy and safety. Rilonacept targets interleukin-1, a pro-inflammatory cytokine that is involved in the pathogenesis of pericarditis, and has demonstrated promising results in small studies. Ongoing clinical trials may provide further insights into the role of rilonacept in the management of pericarditis.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6413712a201352f04a00003e",
			"type": "list",
			"body": "The 1p19q co-deletion is associated with what types of tumors?",
			"chatgpt-out": {
				"queries": ["1p19q co-deletion tumors", "1p19q co-deletion and glioma", "1p19q co-deletion and oligodendroglioma", "1p19q co-deletion and anaplastic oligodendroglioma", "1p19q co-deletion and mixed oligoastrocytoma"],
				"short-ans": "The 1p19q co-deletion is a genetic abnormality that is commonly found in certain types of brain tumors, specifically oligodendrogliomas and mixed oligoastrocytomas. This co-deletion refers to the simultaneous loss of genetic material from the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q). The 1p19q co-deletion has been associated with a better prognosis and increased responsiveness to chemotherapy in patients with oligodendroglioma",
				"long-ans": "The 1p19q co-deletion is a genetic abnormality that is commonly found in certain types of brain tumors, specifically oligodendrogliomas and mixed oligoastrocytomas. The co-deletion refers to the simultaneous loss of genetic material from the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q). The 1p19q co-deletion has been identified as a molecular signature of oligodendrogliomas, and is observed in approximately 50-70% of these tumors. The co-deletion is less common in other types of brain tumors, such as glioblastoma.The 1p19q co-deletion has been associated with a better prognosis and increased responsiveness to chemotherapy in patients with oligodendroglioma. Studies have found that patients with the 1p19q co-deletion tend to have longer overall survival and progression-free survival than patients without the co-deletion. Additionally, patients with the co-deletion have been shown to have a greater response to chemotherapy, particularly with the use of procarbazine, lomustine, and vincristine (PCV) chemotherapy. However, it should be noted that the presence of the 1p19q co-deletion alone is not sufficient to predict treatment response or prognosis, and other factors such as tumor grade and patient age also play a role.In conclusion, the 1p19q co-deletion is associated with certain types of brain tumors, specifically oligodendrogliomas and mixed oligoastrocytomas. The co-deletion has been identified as a molecular signature of oligodendrogliomas, and is observed in approximately 50-70% of these tumors. The presence of the 1p19q co-deletion has been associated with a better prognosis and increased responsiveness to chemotherapy in patients with oligodendroglioma, particularly with the use of PCV chemotherapy. However, other factors such as tumor grade and patient age also play a role in treatment response and prognosis.",
				"exact_answer": ["Oligodendroglioma", "Mixed oligoastrocytoma", "Brain tumors", "Chromosome 1p", "Chromosome 19q", "Molecular signature", "Prognosis", "Chemotherapy", "Overall survival", "Progression-free survival", "PCV chemotherapy", "Treatment response", "Tumor grade", "Patient age", "Genetic abnormality", "Molecular biology", "Neuro-oncology", "Diagnostic biomarker", "Radiotherapy", "Adjuvant chemotherapy"]

			}
		},
		{
			"id": "6429ad3857b1c7a315000003",
			"type": "factoid",
			"body": "The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?",
			"chatgpt-out": {
				"queries": ["Xist gene function", "X-chromosome inactivation mechanism", "Xist gene product", "Xist RNA structure and function"],
				"short-ans": "The X-inactive specific transcript (Xist) gene is responsible for mediating X-chromosome inactivation in female mammals. This process ensures that only one X chromosome is transcriptionally active, which is necessary for normal development and function. The Xist gene encodes a long non-coding RNA that is expressed exclusively from the inactive X chromosome. The Xist RNA transcript is responsible for recruiting a number of proteins and RNA complexes to the inactive X chromosome, which lead to chromatin modifications that ultimately silence gene expression. The Xist RNA transcript plays a crucial role in the mechanism of X-chromosome inactivation in females.",
				"long-ans": "X-chromosome inactivation is a process that ensures equal gene dosage between males and females. In female mammals, one of the two X chromosomes is transcriptionally silenced and inactivated, which is necessary for normal development and function. The X-inactive specific transcript (Xist) gene is responsible for mediating this process.The Xist gene is located on the X chromosome and encodes a long non-coding RNA (lncRNA) transcript that is expressed exclusively from the inactive X chromosome. The Xist RNA transcript is essential for X-chromosome inactivation and is responsible for recruiting a number of proteins and RNA complexes to the inactive X chromosome. The Xist RNA transcript spreads along the X chromosome, coating it in a layer of RNA that leads to chromatin modifications, ultimately resulting in transcriptional silencing of the X chromosome.The exact mechanism by which the Xist RNA transcript mediates chromatin modifications is still not fully understood, but it is known that Xist interacts with a number of protein complexes, including the Polycomb Repressive Complex 2 (PRC2), which methylates histones to promote transcriptional repression. The Xist RNA transcript also recruits the X-chromosome inactivation center (XIC), a locus on the X chromosome that is necessary for X-inactivation.Overall, the Xist gene is responsible for mediating X-chromosome inactivation in females, which is essential for normal development and function. The Xist RNA transcript plays a crucial role in this process by recruiting a number of protein and RNA complexes to the inactive X chromosome, ultimately leading to transcriptional silencing of one of the two X chromosomes.",
				"exact_answer": ["Xist RNA", "Chromatin modifications", "Polycomb Repressive Complex 2", "X-chromosome inactivation center", "Long non-coding RNA"]

			}
		},
		{
			"id": "63f92fd033942b094c00000b",
			"type": "summary",
			"body": "What are microexons?",
			"chatgpt-out": {
				"queries": ["Microexon definition", "Microexon function", "Microexon splicing", "Microexon and neurodevelopmental disorders"],
				"short-ans": "Microexons are a type of alternative exon that are shorter than conventional exons and typically range in size from 3 to 27 nucleotides. They are present in a wide range of genes across different species, including humans. Microexons are often overlooked in gene annotation and expression analysis due to their small size, but recent research has shown that they play an important role in regulating gene expression and protein function.",
				"long-ans": "Microexons are a type of alternative exon that are shorter than conventional exons and typically range in size from 3 to 27 nucleotides. They are present in a wide range of genes across different species, including humans. Despite their small size, microexons are important regulators of gene expression and protein function.Microexons are often overlooked in gene annotation and expression analysis due to their size and low abundance. However, recent studies have shown that microexons play an important role in regulating gene expression and protein function in a variety of ways. For example, microexons can influence protein-protein interactions, alter protein localization, and affect protein stability.Microexons are also involved in the regulation of neuronal development and function. Recent studies have identified microexons in genes that are associated with neurodevelopmental disorders such as autism and intellectual disability. Dysregulation of microexon splicing has been linked to changes in neuronal activity and synaptic function, suggesting a potential role for microexons in the pathogenesis of these disorders.In addition, microexons are subject to tissue-specific regulation, and their splicing patterns can vary between different cell types and developmental stages. This suggests that microexons play an important role in cell type-specific gene expression and protein function.Overall, microexons are an emerging area of research in the field of alternative splicing, and their importance in regulating gene expression and protein function is becoming increasingly apparent.",
				"exact_answer": ""
			}
		},
		{
			"id": "64041f38201352f04a00001f",
			"type": "yesno",
			"body": "Is tebentafusp effective for uveal melanoma?",
			"chatgpt-out": {
				"queries": ["Tebentafusp clinical trials uveal melanoma", "Tebentafusp efficacy uveal melanoma", "Immunotherapy uveal melanoma", "Antigen-specific T-cell therapy uveal melanoma"],
				"short-ans": "Tebentafusp is an immunotherapy drug that is being investigated for the treatment of uveal melanoma, a rare and aggressive form of eye cancer. Tebentafusp works by binding to a protein called gp100, which is expressed on the surface of cancer cells, and triggering an immune response that targets and destroys these cells. Clinical trials of tebentafusp in patients with advanced uveal melanoma have shown promising results, with some patients experiencing durable responses to treatment.",
				"long-ans": "Uveal melanoma is a rare and aggressive form of eye cancer that is difficult to treat using conventional therapies. Tebentafusp is a novel immunotherapy drug that is being investigated for the treatment of uveal melanoma. Tebentafusp works by binding to a protein called gp100, which is expressed on the surface of cancer cells, and triggering an immune response that targets and destroys these cells.Clinical trials of tebentafusp in patients with advanced uveal melanoma have shown promising results. In a phase II clinical trial, tebentafusp demonstrated a statistically significant improvement in progression-free survival compared to the standard of care chemotherapy. In addition, some patients treated with tebentafusp experienced durable responses to treatment, with some patients remaining free from disease progression for more than two years.Tebentafusp is an antigen-specific T-cell therapy that has been shown to induce a robust and durable immune response in patients with uveal melanoma. The drug has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and is currently undergoing further clinical trials to evaluate its efficacy and safety.In summary, tebentafusp is a promising immunotherapy drug that is being investigated for the treatment of uveal melanoma. Clinical trials have shown that tebentafusp can induce a robust and durable immune response in patients with uveal melanoma, and the drug has been granted breakthrough therapy designation by the FDA. Further research is needed to determine the long-term efficacy and safety of tebentafusp in the treatment of uveal melanoma.",
				"exact_answer": "yes"
			}
		},
		{
			"id": "6426bb49690f196b5100004d",
			"type": "summary",
			"body": "What is the Fenton reaction",
			"chatgpt-out": {
				"queries": ["Fenton reaction mechanism", "Hydroxyl radical generation in Fenton reaction", "Fenton reaction and oxidative stress", "Iron-catalyzed reactions in biological systems"],
				"short-ans": "The Fenton reaction is a type of chemical reaction that involves the generation of highly reactive hydroxyl radicals from hydrogen peroxide in the presence of iron ions. The reaction proceeds as follows: Fe(II) + H2O2 → Fe(III) + •OH + OH-. The hydroxyl radicals generated in the Fenton reaction are highly reactive and can cause damage to biological molecules, such as lipids, proteins, and DNA. The Fenton reaction is an important source of oxidative stress in biological systems and has been implicated in a variety of diseases, including cancer, neurodegenerative disorders, and cardiovascular disease",
				"long-ans": "The Fenton reaction is a type of chemical reaction that involves the generation of highly reactive hydroxyl radicals from hydrogen peroxide in the presence of iron ions. The reaction proceeds as follows: Fe(II) + H2O2 → Fe(III) + •OH + OH-. The hydroxyl radicals generated in the Fenton reaction are highly reactive and can cause damage to biological molecules, such as lipids, proteins, and DNA.The Fenton reaction is an important source of oxidative stress in biological systems and has been implicated in a variety of diseases, including cancer, neurodegenerative disorders, and cardiovascular disease. Excessive production of hydroxyl radicals via the Fenton reaction can lead to oxidative damage to cells and tissues, and has been suggested to play a role in the aging process.Iron ions are ubiquitous in biological systems and can catalyze a variety of reactions, including the Fenton reaction. While the Fenton reaction can be beneficial in certain contexts, such as in the immune response to infection, it can also have harmful effects in other situations. For example, the Fenton reaction has been implicated in the pathogenesis of several diseases, including Alzheimer's disease, Parkinson's disease, and atherosclerosis.In summary, the Fenton reaction is a type of chemical reaction that generates highly reactive hydroxyl radicals from hydrogen peroxide in the presence of iron ions. The reaction is an important source of oxidative stress in biological systems and has been implicated in a variety of diseases. Further research is needed to better understand the role of the Fenton reaction in health and disease, and to develop strategies to modulate the reaction for therapeutic purposes.",
				"exact_answer": "no"
			}
		}
	]
}